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ABSTRACT 
The onset of resistance to cisplatin still limits its use in the chemotherapy of ovarian cancer and, 
despite several mechanisms of resistance have been discovered, they are not exhaustive. The aim 
of this study was to identify which other pathways are exploited by cancer cells to escape cisplatin 
cytotoxicity, to possibly prevent or overcome the phenomenon with new pharmacological 
approaches. The increase of anaerobic glycolysis, even in the presence of oxygen (Warburg 
effect), is the first observation indicating the alteration of energetic metabolism used by tumor 
cells as a strategy to adapt and grow independently from the availability of the substrate. This 
evidence suggested us to investigate the hypothesis that a similar metabolic strategy might be of 
relevance in resistance to cisplatin. Recently it has been shown that only approximately 1% of 
intracellular platinum is bound to nuclear DNA, while the great majority of the intracellular drug is 
available to interact with other nucleophilic sites including but not limited to phospholipids, 
cytosolic, cytoskeletal and membrane proteins, RNA and mitochondrial DNA. mtDNA, unlike 
nDNA, does not possess efficient repair systems and is therefore more susceptible to the onset of 
mutations often associated to cancer development, loss of tumor suppressor, activation of 
oncogenes and mitochondrial dysfunctions often related with an increase of glycolytic activity. 
Therefore, the aim of this study was to investigate the energetic metabolism and the 
mitochondrial function of cisplatin-resistant (C13) and sensitive (2008) ovarian cancer cells with 
different experimental approaches. Results revealed that resistant cells present a significant 
reduced respiratory chain activity correlated to a lower mitochondrial mass, altered mitochondrial 
morphology as well as a metabolomic profile typical of a lipogenic phenotype. To investigate the 
role of mtDNA and nDNA in the mitochondrial and metabolic remodeling of cisplatin-resistant 
line, cancer cells (2008-C13) were used to generate transmitochondrial hybrids (H2008-HC13). 
Mitochondrial DNA of parental and hybrid cells was sequenced, showing similar, almost non 
pathological, polymorphisms. Interestingly, investigating the energetic metabolism and the 
mitochondrial structure of hybrids, no differences were observed between H2008 and HC13. 
These data demonstrated that the metabolic reprogramming of C13 cells was not dependent 
from mtDNA, but was controlled by nuclear factors. Having regard to these data, the activity of 
some nuclear transcription factors (HIF-1α, and c-Myc) involved in the metabolic reprogramming 
of tumor cells, has been evaluated and it has been highlighted a different expression of some of 
their target genes involved in the glycolytic flux. Finally, the metabolic profile of 2008-C13 cells 
has been outlined by LC-MS which evidenced some interesting differences in aminoacids, 
phospholipids and antioxidants content. 
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RIASSUNTO 
L’utilizzo del cisplatino nel trattamento del cancro all’ovaio è tutt’oggi limitato dall’insorgenza di 
chemioresistenza. Nonostante siano stati evidenziati numerosi meccanismi implicati nella 
resistenza al cisplatino, questo fenomeno non è ancora stato del tutto chiarito. Lo scopo di questo 
studio è stato quindi quello di identificare quali altre strategie vengano sfruttate dalle cellule 
tumorali per sfuggire alla citotossicità indotta dal cisplatino in modo da prevenire o superare la 
resistenza attraverso l’utilizzo di nuovi approcci farmacologici. L'aumento della glicolisi 
anaerobica, anche in presenza di alte concentrazioni di ossigeno (effetto Warburg), è la più nota e 
meglio conosciuta alterazione del metabolismo energetico utilizzato dalle cellule tumorali come 
strategia per adattarsi e crescere in modo indipendente dalla disponibilità del substrato. Queste 
evidenze scientifiche ci hanno suggerito di indagare l'ipotesi che una simile strategia possa essere 
rilevante nell’insorgenza della resistenza al cisplatino. Recentemente è stato dimostrato che solo 
~1% del platino intracellulare si lega al DNA nucleare, mentre la gran parte del farmaco 
interagisce con altri siti nucleofili tra cui fosfolipidi, proteine di membrana, RNA e DNA 
mitocondriale. Il mtDNA, a differenza del nDNA, non possiede sistemi di riparazione efficaci ed è 
quindi più suscettibile all’insorgenza di mutazioni e trasformazioni oncogeniche spesso associate 
allo sviluppo del cancro, perdita di oncosoppressori, attivazione di oncogeni e ad alterazioni della 
funzionalità mitocondriale correlata ad aumento dell'attività glicolitica. Pertanto, l'obiettivo di 
questo studio è stato quello di studiare il metabolismo energetico e la funzione mitocondriale 
delle cellule di cancro ovarico sensibili (2008) e resistenti (C13) al cisplatino utilizzando diversi 
approcci sperimentali. I risultati hanno evidenziato che le cellule resistenti presentano una 
significativa riduzione dell'attività della catena respiratoria correlata ad una minore massa 
mitocondriale, alterata morfologia mitocondriale nonché un profilo metabolico tipico di un 
fenotipo lipogenico. Per studiare il ruolo del mtDNA e del nDNA nel rimodellamento metabolico e 
mitocondriale osservato nella linea resistente al cisplatino, le cellule tumorali (2008-C13) sono 
state utilizzate per generare ibridi transmitocondriali (H2008-HC13). Il DNA mitocondriale delle 
cellule parentali e degli ibridi citoplasmatici è stato quindi sequenziato, mostrando polimorfismi 
simili, ma non patologici. È interessante notare che, le differenze metaboliche e mitocondriali 
evidenziate nelle linee tumorali, non vengono mantenute nei rispettivi cibridi dimostrando che la 
riprogrammazione metabolica delle cellule C13 non è influenzata dal mtDNA, ma è controllata da 
fattori nucleari. Alla luce di tali dati, è stata quindi valutata l’attività di alcuni noti fattori di 
trascrizione (HIF-1α e c-Myc) coinvolti nella riprogrammazione metabolica delle cellule tumorali 
ed è stata evidenziata una diversa espressione di alcuni dei loro geni target implicati nel flusso 
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glicolitico. Infine il profilo metabolico delle linee 2008-C13 è stato delineato mediante LC-MS da 
cui sono emerse interessanti differenze nel contenuto lipidico, amminoacidico e di alcuni noti 
agenti antiossidanti. 
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ABBREVIATIONS 
Abs Absorbance 
ACLY ATP citrate lyase 
BrdU Bromodeoxyuridine  
BSO Buthiomine Sulfoximine 
CA-125 Cancer Antigen 125 
CDDP Cis-diamminedichloroplatinum II 
CL  Cardiolipin 
DMEM  Dulbecco's modified Eagle's medium 
ERCC1 Excision Repair Cross-Complementation 1 
EtBr Ethidium Bromide 
FAs  Fatty Acids 
FAS Fatty Acid Synthase 
FBS Fetal Bovine Serum 
FDG-PET 18F-deoxyglucose Positron Emission Tomography 
FIGO International Federation of Gynecology and Obstetrics 
F6P  Fructose-6-phosphate 
gDNA Genomic DNA 
GOG Gynecologic Oncology Group 
G6P Glucose-6-phosphate 
G6PD Glucose-6-phosphate dehydrogenase 
Grx Glutaredoxin 
GSH Glutathione 
HGSC High-grade Serous Carcinomas  
HIF Hypoxia Inducible Factor 
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HK2  Hexokinase 2 
Hsp90 Heat shock protein 90 
IDH Iisocitrate dehydrogenase 
LC-MS Liquid Chromatography–Mass Spectrometry 
LGSC Low-grade Serous Carcinomas  
LKB1 Liver kinase B1 
MEF Mouse Embryonic Fibroblasts 
MFI Mean Fluorescence Intensity 
ML Mobile lipid 
MMR mismatch repair 
mRNA Messenger RNA 
MRP Multi-drug Resistance Protein 
MOA Mechanism of Action 
MT Metalothioneins 
mtDNA Mitochondrial DNA 
MTG MitoTracker Green 
MTT [3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide  
NAO 10-Nonyl bromide acridine orange 
nDNA Nuclear DNA 
NEAA Not essential Aminoacid 
NER Nucleotide Excision Repair 
NMR Nuclear Magnetic Resonance  
OC Ovarian Cacinoma 
OXPHOS Rational Treatment Strategies Combating Mitochondrial Oxidative 
Phosphorylation  
PEG Polyethylene glycol 
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Pen/Strep Pennicilin-streptomycin 
PBS Phosphate buffered saline 
PC Phosphacholines 
PCA Principal Component Analysis  
PDH Pyruvate Dehydrogenase 
PE Phosphaethanolamines 
PFK1 Phosphofructokinase 1 
PPP Pentose phosphate pathway 
PS Phosphatidylserine 
PVDP Polyvinylidene fluoride  
qRT-PCR Quantitative Real-time Polymerase Chain Reaction 
Rh123 Rhodamine-123 
RNAi RNA interference 
ROS Reactive Oxygen Species 
R5P Ribose-5-phosphate  
SDS Sodium dodecyl sulfate 
Ser/Thr Serine/Threonine 
TCA tricarboxylic acid  
TK- Tyrosin-kinase deficient 
TMRM Tetramethyl Rhodamine Methyl Ester 
Trx  Thioredoxin 
VHL  Von Hippel-Linau 
WHO  World Health Organization 
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INTRODUCTION 
1. OVARIAN CANCER 
Ovarian cancer (OC) is one of the most aggressive and lethal gynecological cancers [Jemal A. et al., 
(2007)] with a 5-year survival rate of approximately 45%. Around the world, more than 200.000 
women are estimated to develop ovarian cancer every year and about 100.000 die from the 
disease. Epithelial ovarian cancer occurs most commonly in white women in the developed word 
and the mean age of occurrence is 56 years old [Green A. E. and Garcia A. A., (2012)].  
The symptoms related to ovarian cancer, including abdominal pain, swelling or indigestion are 
quite vague and not disease specific [Lim M.C et al., (2009); Lim M.C. et al. (2010)] and although 
serum tumor markers, such as CA-125, and transvaginal ultrasonography can detect ovarian 
cancer, only fewer of 25% of ovarian cancer are found in the early stages and in the most cases 
the disease has already spread beyond the ovaries at the time of the diagnosis [Andersen M.R. et 
al., (2008)].  
1.1 Etiology 
Despite considerable efforts aimed at elucidating the molecular mechanisms of ovarian carcinoma 
(OC), the origin and the pathogenesis of this disease are still poorly understood [Kurman R.J. and 
Shih I. M., (2010)], however several risk and contributing factors have been identified. 
Reproductive factors. The protective effect of parity on ovarian cancer risk is well-documented. 
Women who have been pregnant have a 50% decreased hazard for developing ovarian cancer 
compared with nulliparous women and multiple pregnancies seem to offer an increasingly 
protection [Whittemore A.S. et al., (1992)]. These findings support the idea that the ovarian 
cancer incidence is correlated with the number of ovulations and two theories regarding this 
relationship have been proposed. The incessant ovulation theory suggests that repeated mitotic 
activity required to repair the epithelial trauma caused by follicular rupture results in genetic 
alterations that can lead to malignant transformation [Murdoch W.J., (2003)]. The gonadotropin 
theory proposes that persistent stimulation of the ovaries by gonadotropins, coupled with local 
effects of endogenous hormones, increases surface epithelial proliferation and subsequent 
mitotic activity. Thus, factors that decrease the ovulatory cycles, such as pregnancy, lactation and 
the use of oral contraceptives, usually might have a protective role in the appearance of ovarian 
10 
 
cancer, while nulliparity and hormone therapies against infertility may lead to an increased 
ovarian cancer risk [Rossing M.A. et al. (2004); Morch L.S. et al. (2009)]. 
Genetic factors. The greatest risk factors of ovarian cancer are the family history and the 
associated genetic syndromes that are involved in the 10% of the cases. The hereditary 
component of ovarian cancer appears to be due to BRCA (BRCA1-BRCA2) mutations in hereditary 
breast-ovarian cancer syndrome [Yoshida and Miki (2004); Yang et al., (2011)] and to hMLH1 and 
hMLH2 mutations in hereditary non-polyposis colorectal cancer syndrome (HNPCC or Lynch II) 
[Bonadonna et al. (2011)]. The risk of a woman with a BRCA1 mutation developing ovarian cancer 
is between 36% and 46%; that of a woman with a BRCA2 mutation is estimated between 10% and 
27% [Rebbeck T.R. et al., (2009)]. Both genes play important roles in genomic stability and 
integrity, in cell cycle control and in the apoptosis. Specifically, both genes are essential for DNA 
repair and activation of cell cycle checkpoint control (Figure 1). Repair-deficient cells (without 
BRCA genes) may accumulate molecular and chromosomal changes with consequent 
development and progress of cancer. 
 
 
 
Even if BRCA germline mutations are the most frequent in ovarian cancer, data indicate that each 
of the histologic OC subtypes is characterized by distinct histogenetic signatures and a unique 
complement of chromosomal abnormalities. High-grade serous (HGSC) and possibly endometrioid 
carcinomas most probably arise from surface epithelial inclusion glands with TP53 mutations and 
dysfunction of BRCA1 and/or BRCA2 [Kolasa et al., (2006); Salani et al., (2008)]. In contrast, low-
grade serous ovarian carcinomas (LGSC) harbour alterations in KRAS, BRAF and/or HER-2 genes, 
implying a different route of carcinogenesis [Singer et al., (2003)]. Mucinous carcinomas arise via 
Fig. 1: Diagram illustrates the role of BRCA and mismatch repair (MMR) 
genes in DNA repair and in the pathogenesis of hereditary cancers.  
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an adenoma–borderline tumor–carcinoma sequence with mutations in KRAS while the 
characteristic genetic alterations of endometrioid carcinomas are mutations of the catenin gene 
(CTNNB1), PTEN and TP53. 
Others factors. Although the incidence rate of ovarian cancer in Japan is significantly lower than in 
western countries, a remarkable change in lifestyle after World War II has increased the mortality 
rate by almost 4 fold [Li X.M. et al., (2003)]. This observation suggests that lifestyle may play a role 
in the etiology of ovarian cancer. There is some evidence that smoking, physical activity, diet, 
alcohol consumption and the exposure to certain environmental agents (talc, pesticides, and 
herbicides) may affect ovarian cancer risk. Some studies have suggested that animal derived food, 
such as red meat, milk, and eggs may increased serum gonadotropins (FSH and LH), which may 
increase the risk of ovarian cancer by directly stimulating cell proliferation and inhibiting 
apoptosis in the ovarian surface epithelium [Konishi I. et al., (1999)], but most studies have not 
identified a role for dietary fat and galactose intake in the development of ovarian cancer. 
Nonetheless, some studies have suggested that saturated fat consumption may result in an 
increased risk of epithelial ovarian cancer [Huncharek M. and Kupelnick B., (2001)]. A case-control 
study in Italy has shown that starch was directly associated with the risk of ovarian cancer and 
that unsaturated fatty acids were inversely associated with ovarian cancer risk [Bidoli E. et 
al.,(2002)]. 
1.2 Classification of ovarian neoplasms 
The origin of ovarian cancer lies in the cells that constitute the ovaries including surface epithelial 
cells 85-90%), sex cord-stromal cells (~6%) and germ cells (<1%). The classification of ovarian 
epithelial tumors currently used, is based entirely on tumor cell morphology. Because of their 
complicated histological structure, ovaries produce several subtypes of malignant and benign 
tumors [Soslow R.A., (2008)]. The most common ovarian neoplasm is epithelial cancer which is 
traditional thought to arise from epithelium covering the ovaries. Five main histologic subtypes, 
which classification is entirely based on cell morphology, arise in the epithelial lining of the cervix, 
uterus, and fallopian tube, as follows: serous (fallopian tube); endometrioid (endometrium); 
mucinous (cervix); clear cell (mesonephros); Brenner. 
Serous cystadenocarcinoma. This type is the most common, accounting for 40-50% of cases 
[Heintz A.P. et al., (2001); Quirk J.T.and Natarajan N., (2005)]. Most HGSCs arise de novo from 
tubal-ovarian epithelium, do not appear to be associated with macroscopic precursors and 
manifest with widely disseminated disease at presentation. LGSCs arise in a stepwise fashion from 
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cyst-adenomas and serous borderline tumors and are commonly diagnosed in the early stages of 
disease [Lalwani N. et al., (2011)]. 
Endometrioid adenocarcinoma. These tumors are malignant in 80% of cases, and represent 25% 
of all ovarian cancers and they have a strong association with both pelvic and ovarian 
endometriosis [De Priest P.D. et al., (1992)]. 
Mucinous cystadenocarcinoma. Traditionally they accounted for approximately 10% of all ovarian 
cancers, although this rate is now thought to be lower. Overall they have a relatively favorable 
prognosis probably because they are mostly confined in the ovary.  
Clear Cell adenocarcinoma. They represent approximately 5% of ovarian cancers [Heintz A.P. et 
al., (2001); Quirk J.T.and Natarajan N., (2005)]; they are strongly associated with pre-existing 
endometriosis [Kennedy E.W. et al., (1989)] and they tend to present earlier in comparison with 
the other subtypes. Low response rate to chemotherapeutic drugs is typical for clear cells 
carcinoma. 
Undifferentiated carcinomas. A significant number of epithelial ovarian cancers (5-25%) are 
termed unclassified or undifferentiated because their cells are so underdeveloped that is not 
possible to tell where they have originated.  
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Epithelial ovarian cancer are also classified based on their grade and stage. Historically, the most 
commonly used grading systems have been those proposed by the International Federation of 
Gynecology and Obstetrics (FIGO), the World Health Organization (WHO), and the Gynecologic 
Oncology Group (GOG) [Cho K.R. and Shi I.M., (2009)]. The FIGO classification of ovarian 
carcinoma staging (1989) is shown in Table 1.  
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1.3 Current treatments of ovarian cancer 
In the last decades, survival of patients with ovarian cancer has improved due to new cytostatic 
agents and to advances in surgical strategies. Treatment and prognosis depend on the type of 
ovarian cancer and how far it has spread at the time of the diagnosis [Cho K.R. and Shi I.M., 
(2009)]. Surgery, whose aim is to confirm the diagnosis, define the extent of disease, and resect 
all visible tumor, is the initial treatment of choice, but only a small percentage of women with 
epithelial ovarian cancer can be treated with surgery alone. These include patients with stage IA 
grade 1 and stage IB grade 1 serous, mucinous, endometrioid, and Brenner tumors. Clear-cell 
carcinomas are associated with a significantly worse prognosis in stage I, and patients with this 
histologic subtype should be considered for chemotherapy at all stages. The standard treatment 
of advanced ovarian cancer involves surgical resection followed by cycles of adjuvant 
chemotherapy with a combination of taxane and platinum compounds [Bookman M., (2005)]. 
Radiation has not been widely accepted as a routine treatment modality in the initial treatment of 
patients with epithelial ovarian cancer, despite reports of efficacy for higher-risk stage I and II 
disease and in stage III disease where small-volume residual disease is present after surgery. In 
selected cases, pelvic diseases may respond to palliative dosing regimens with minimal toxicity. 
Currently, the first-line treatment for ovarian cancer is a combination chemotherapy: usually a 
platinum-based drug, such as cisplatin or carboplatin, coupled with paclitaxel [Joerger M. et al., 
(2007); Vella N. et al., (2011)]. The mechanism of action (MOA) of paclitaxel is to stabilize 
microtubules and as a result it induces mitotic arrest and apoptosis [Xiao H. et al., (2006)]; 
instead, the MOA of carboplatin is to bind DNA and to form intra-strand crosslinks, inhibiting DNA 
replication and transcription [Wang D. et al, (2005)]. Despite high initial response rates, a large 
proportion of patients relapse or develops chemoresistance, resulting in a therapeutic challenge. 
[Fung-Kee M. et al., (2007)]. Unraveling the underlying mechanisms causing chemoresistance is 
crucial for personalized therapy and the improvement of patients long-term survival. 
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2. CISPLATIN  
Cis-diamminedichloroplatinum II, best known as cisplatin (CDDP), is one of the most potent 
anticancer agents used in the treatment of various solid tumors including testicular, ovarian and 
lung cancer [Galanski M., (2006)]. Although the synthesis and the characterization of cisplatin was 
first reported by Peyrone in 1845, its anticancer properties was casually discovered in the middle 
of 1960s, when Rosenberg and co-workers studied the effects of electric fields on Escherichia coli 
growth [Rosenberg B. et al., (1965)]. Cisplatin cytotoxicity is believed mainly due to the ability to 
form inter- and intra-strand nuclear DNA crosslinks that, hindering both RNA transcription and 
DNA replication, can lead to cell cycle arrest and apoptosis [Wang D. et al., (2004)]. Even if the 
clinical benefits of cisplatin are largely recognized, the therapeutic effectiveness of the drug is 
limited by the severity of its side effects (ototoxicity, nephrotoxicity and neurotoxicity) [Pasetto 
L.M. et al., (2006)], and by the potential progression of tumor cells to a cisplatin-resistant state 
[Koberle B. et al., (2010)].  
2.1 Mechanism of action 
Cisplatin is a relatively simple planar compound consisting of a platinum atom complexed by two 
ammine groups and two chloride ions (Fig. 2). 
Drug Accumulation. Once CDDP is intravenously 
administered to the patient, it rapidly diffuses into 
tissues and is highly bound to plasma proteins. Binding 
of cisplatin to plasma proteins is a result of the strong 
reactivity of platinum against sulphur of thiol groups of 
amino acids such as cysteine. Hence, near 90 % of the 
platinum in the blood is bound to albumin and other 
plasma proteins (es. gamma-globulins and transferrin) leading to inactivation of a great amount of 
cisplatin molecules [Judson I. and Kelland L.R., (2000)]. In blood, where the chloride concentration 
is relatively high (~100 mM), cisplatin exists mainly in the dichloro neutral form. Loss of the 
chloride groups from the cisplatin molecule is required for intracellular CDDP activity. When the 
neutral compound enter the cell, the relatively low chloride concentration (2-30 mM) favours the 
replacement of one or both chloride leaving groups by water, resulting in a positively charged 
molecule mono and diaquo species ([Pt(H2O)Cl (NH3)2]
+ and [Pt(H2O)2(NH3)2]
2+ cations) that reacts 
with nucleophilic molecules such as DNA,RNA and proteins [Kartalou, M. and Essigmann, J. M. 
(2001)]. 
Fig. 2: cis-diamminedichloroplatinum II  
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The biochemical mechanism by which cisplatin crosses the cell membrane still remains unclear. 
Early studies reported that cisplatin uptake was not inhibited by their structural analogues and 
the entry into the cell did not seem to be dependent on an optimum pH [Binks S.P. et al. (1990)]. 
On the other hand, it has been demonstrated that the uptake can clearly be modulated both by a 
variety of pharmacologic agents that do not cause general permeabilization of the membrane, 
and by activation of some intracellular signal transduction pathways. Thus, it has been proposed 
that ~50% of the initial rate of uptake is due to passive diffusion and the remaining 50% to 
facilitated diffusion through a gated channel [Gately D. P. and Howell S. B., (1993)] and growing 
evidences indicate that a copper transporter is involved [Ishida S. et al., (2002)], leading to 
propose an active transport for cisplatin in addition to passive diffusion (Fig. 3).  
 
 
 
 
Binding to DNA. Experimental data accumulated over the last 35 years, indicate that DNA is the 
preferential and cytotoxic target of cisplatin blocking DNA replication, inducing G2 cell cycle 
arrest, inhibiting RNA transcription and finally promoting cell death through apoptosis [Zorbas H. 
and Keppler B.K., (2005), Eastman A., (1999)]. When binding to DNA, CDDP favors the N7 atoms of 
the imidazole rings of guanosine and adenosine, that are the most accessible and nucleophilic 
reactive sites for platinum coordination to DNA. As shown in Fig. 4, cisplatin may form several 
Fig. 3: Schematic cisplatin uptake and efflux and binding to nuclear DNA. In addition to 
passive diffusion, cisplatin is also actively uptaked through the copper transporter CTR1. 
Copper-transporting P-type adenosine triphosphate (ATP7B) is involved in cisplatin efflux. 
Both copper and cis-DDP show the ability to decrease the import of the other and can 
induce the degradation and delocalization of CTR1. Once cis-DDP is in the cytoplasm, it may 
be inactivated by gluthathione (GSH) or may bind to its main cellular target, nuclear DNA. 
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types of lesions on purine bases of DNA: monoadducts and bifunctional adducts called intrastrand 
or interstrand crosslinks [Payet D.G. et al.; (1993)]. 
 
 
 
 
Monoadducts are the first formed, however, greater than 90% of monoadducts then react to 
form crosslinks. Almost 60-65% of these crosslinks are 1,2-d(GpG) intrastrand while 20-25% are 
1,2-d(ApG) intrastrand cross-links. It has been recently shown that the minor 1,3-d(GpTpG) 
intrastrand cross-link could be also important in the mechanism of action of cisplatin. In fact, the 
minor 1,3-d(GpTpG) intrastrand cross-link adduct induces in nucleosomes an asymmetric 
arrangement of the DNA in relation to the histone octamer, which affects the translational 
positioning of the DNA. All crosslinks result in contortion of the DNA [Fuertes M.A. et al., (2003)]. 
Both 1,2-d(GpG) and 1,2-d(ApG) intrastrand crosslinks unwind DNA by 13°, while the 1,3-
d(GpXpG) intrastrand lesion unwinds DNA by 34°. Interstrand lesions induce even more steric 
changes in DNA, with extrusion of the cytosines at the crosslinked d(GpC)d(GpC) sites, bending of 
the double helix toward the minor groove by 20-40°, and extensive DNA unwinding of up to 80°. 
Binding to non-DNA targets. When the drug passes through the cell membrane, the cis-Pt(II) 
center may coordinate to some constituents of the lipidic bilayer, which contain nitrogen and 
sulphur atoms including phospholipids and phosphatidylserine [Speelmans G. et al., (1997)]. In the 
cytoplasm many cellular components that have soft nucleophilic sites such as cytoskeletal 
microfilaments, RNA and thiol-containing peptides and proteins may react with cisplatin [Jordan 
P. and Carmo-Fonseca M., (2000); Arnesano F. and Natile G., (2008)]. Hence, of interest is the 
observation that only 5-10% of covalently bound cell-associated cisplatin is found in the gDNA 
Fig. 4: Main adducts formed after binding of cis-DDP to DNA. (A) 1,2-intrastrand 
cross-link, (B) interstrand cross-link, (C) monofunctional adduct, and (D) protein-
DNA cross-link. The main site of attack of cis-DDP to DNA (N7 of guanine) is shown 
in the central panel 
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fraction, whereas 75-85% of the drug binds to proteins and other cellular constituents. The most 
important non-DNA target of cisplatin is probably the tripeptide glutathione (GSH) which is 
present in cells at high concentrations (0.5-10 mM). GSH and other thiol-containing biomolecules 
such as metalothioneins (MT) bind quickly to platinum. Cisplatin binding to GSH and MT has 
primarily been associated with negative pharmacological properties, including the development 
of resistance and toxicity. On the other hand, cisplatin may alter the activity of enzymes, 
receptors, and other proteins through coordination to sulfur atoms of cysteine and/or methionine 
residues and to nitrogen atoms of histidine residues [Arnesano F. and Natile G., (2008)]. In fact, 
binding of cisplatin to N-terminal methionine (Met1) and histidine (at position 68) of ubiquitin 
may inhibit the ubiquitin-proteasome pathway of selective degradation of cellular proteins, which 
ends up in cytotoxic events [Peleg-Shulman T. and Gibson D. J., (2001)]. In addition, it has been 
found that cisplatin, besides inhibiting in vitro the activity of heat shock protein 90 (Hsp90), an 
ATP-binding chaperone, efficiently and specifically blocks its C-terminal ATP binding site. The C-
terminal of Hsp90 via its ATP hydrolytic function is involved in the correct folding of proteins 
which play a role in signal transduction and cell cycle regulation [Soti C. et al., (2002)].  
Signaling cascades and transcription factors. A number of additional properties of cisplatin are 
now emerging including activation of signal transduction pathways leading to apoptosis. Firing of 
such pathways may originate at the level of the cell membrane after damage of receptor or lipid 
molecules by cisplatin, in the cytoplasm by modulation of proteins via interaction of their thiol 
groups with cisplatin or finally from DNA damage via activation of the DNA repair pathways 
[Boulikas T. and Vougiouka M., (2003)]. It was found that AKT, c-Abl, p53, MAPK/JNK/ERK/p38 and 
related pathways respond to presence of DNA lesions [Cepeda V. et al. (2007); Wang D. and 
Lippard S.J., (2005)]. AKT molecule, as most important Ser/Thr protein kinase in cell survival, 
protects cells from damage induced by different stimuli as well as by cisplatin [Datta S.R. et al., 
(1999)]. Cisplatin downregulates XIAP protein level and promotes AKT cleavage resulting in 
apoptosis in chemosensitive but not in resistant ovarian cancer cells [Fraser M. et al., (2003); Dan 
H. C. et al., (2004)]. Recently published data about synergistic effect of XIAP, c-FLIP, or NFkB 
inhibition with cisplatin are mainly mediated by AKT pathway [Viniegra J.G. et al. (2002)]. Protein 
marked as the most important in signaling of the DNA damage is c-Abl which belongs to SRC 
family of non-receptor tyrosine kinases [Cepeda V. et al. (2007); Wang D. and Lippard S.J., (2005)]. 
This molecule acts as transmitter of DNA damage triggered by cisplatin from nucleus to cytoplasm 
[Shaul Y., (2000)]. Moreover, sensitivity to cisplatin induced apoptosis is directly related with c-Abl 
content and could be blocked by c-Abl overexpression [Wang D. and Lippard S.J., (2005)].  
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Cisplatin induces oxidative stress and is an activator of stress-signaling pathways especially of the 
mitogen activated protein (MAP) kinase cascades. Cisplatin induces caspase activation in 
enucleated cells (cytoplasts lacking a cell nucleus) in a mechanism associated with rapid induction 
of cellular reactive oxygen species and increases in Ca2+, induces clustering of Fas/CD95 in the 
plasma membrane, long-term growth arrest ("premature cell senescence"), and mitotic 
catastrophe [Havelka et al, (2007)]. Cisplatin induced E-cadherin cleavage resulting in 
disconnection of the actin cytoskeleton and accumulation of E-cadherin and beta-catenin in the 
cytoplasm.  
2.2 Cisplatin resistance 
Acquired resistance due to mutations and epigenetic events hinders the effectiveness of platinum 
drugs in the treatment of cancer, causing cancer relapse, failure of subsequent treatments and 
eventual death of patients. As shown in Fig. 5, resistance to cisplatin is generally considered a 
multifactorial phenomenon, which is mainly due to: 1. reduced drug accumulation; 2. inactivation 
by thiol containing species; 3. increased repair of platinum-DNA adducts; 4. increase of cisplatin 
adducts tolerance and failure of cell death pathways [Rabik C.A. and Dolan M.E., (2007); Boulikas 
T. et al., (2007)]. These mechanisms are cell line-dependent so that a particular tumor may exhibit 
one, two or even all the above-mentioned mechanisms [Kelland L.R. et al., (2000)].  
 
 
 
 
Figure 5. Cisplatin resistance mechanisms. Cisplatin is a neutral complex which on entering the 
cell becomes positively charged, and so able to interact with many molecules including DNA and 
proteins. Many mechanisms may contribute to cisplatin resistance including reduced uptake, 
increased efflux, increased detoxification, inhibition of apoptosis, increased ability to replicate 
past DNA adducts and increased DNA repair. GS–Glutathione, Pol–Polymerase. 
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Reduced drug accumulation. The major mechanism of resistance to cisplatin is a decreased 
effective concentration of intracellular drug, reduced from 20-70% [Siddik Z.H., (2003)]. This can 
be due either to decreased influx or increased efflux. It has long been presumed that cisplatin is 
taken up passively by the cell, as uptake is not saturable, nor is it inhibited by structural analogs. 
Interestingly, however, ouabain, a small molecule which inhibits the membrane 
sodium/potassium ATPase pump, blocks cisplatin import, indicating that cisplatin uptake may be 
dependent on the membrane potential of the cell [Andrews P.A. et al., (1988)]. Additionally, 
benzaldehyde and similar aldehyde molecules decrease intracellular accumulation of cisplatin by 
inhibiting uptake, thought to occur through formation of Schiff bases with integral membrane 
transport proteins [Dornish J.M. et al., (1985); Dornish J.M. et al., (1986); Dornish J.M. et al., 
(1989); Pettersen E.O. et al. (1986)]. 
Cisplatin, at plasma concentrations, not only prevents copper from being transported by the high-
affinity copper transporter Ctr1, but also downregulates protein expression of Ctr1 in human 
ovarian carcinoma cell lines [Holtzer A.K. et al., (2004)]. More evidence for the role of copper 
transport in cisplatin sensitivity is based on the observation that cisplatin and copper are 
competitive inhibitors for the transport of the other molecule into the cell [Holtzer A.K. et al., 
(2004)]. Mouse embryonic fibroblasts (MEF) null for CTR1 provide 3.2-fold increased resistance as 
compared with transfected cells. Two other copper transporters have also been implicated in 
resistance to cisplatin: ATP7A/B shuttle copper between the Golgi and the plasma membrane. 
ATP7B was first proposed to be involved in cisplatin resistance when Komatsu et al. 
overexpressed this transporter in human epidermoid carcinoma cells and observed that these 
cells gained approximately 60% resistance to cisplatin more than cells transfected with empty 
vector [Komatsu M. et al., (2000)]. In human ovarian tumors, SKOV3, OMC6, and PA1 cells exhibit 
high ATP7B expression levels and SKOV3 cells, exhibiting the highest level of ATP7B expression, 
also showed the highest resistance to cisplatin [Nakayama K. et al, (2001)]. Additionally, eighty-
two primary ovarian carcinomas were profiled for expression of several known resistance genes 
including ATP7B, MDR1, MRP1, MRP2, LRP, and BCRP [Nakayama K. et al, (2002)]. With the 
exception of ATP7B, none were indicators for resistance of ovarian cancer to cisplatin. Patients, 
whose carcinomas expressed high levels of ATP7B, had a significantly poorer prognosis than 
patients with tumors that expressed low levels of ATP7B [Nakayama K. et al, (2001)]. Additionally, 
it has been shown that at least one additional resistant ovarian cell line, IGROV-1/CP exhibited 
increased expression of ATP7B [Katano K. et al., (2002)]. ATP7A is able to sequester into vesicles 
not only cisplatin, but also both carboplatin and oxaliplatin. Increased expression of ATP7A in the 
2008 line (2008/MNK) leads to increased resistance to all three of these agents; interestingly, 
overexpression leads to increased sequestration of platinating agents and not to decreased total 
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accumulation [Samimi G. et al., (2004)]. ATP7A is overexpressed as measured by protein levels in 
some cisplatin-resistant ovarian carcinoma cell lines [Katano K. et al., (2002)]. In two cell lines, 
A2780/CP and 2008/C13*5.25 overexpression of ATP7A was shown to be causative for resistance 
to cisplatin. In addition to the copper transporters, the multi-drug resistance protein (MRP) is 
thought to function as an ATP-dependent pump for many drugs, including cisplatin [Ishikawa T. 
Ishikawa T. and Ali-Osman F., (1996); Lautier D. et al., (1996)]. In rat hepatocyte cell lines treated 
with cisplatin, MRP-2 protein and mRNA levels increased approximately 3-fold upon treatment 
with cisplatin [Schrenk D. et al., (2001)]. Cisplatin also slightly increased the mRNA expression of 
MRP3, but did not affect MRP1 expression [Ishikawa T. et al., (1996); Schrenk D. et al., (2001)]. 
Using sensitive and resistant melanoma cell lines, MRP2 expression was shown to be upregulated 
in the cisplatin-resistant cell lines as compared to the sensitive line [Liedert B. et al., (2003)].  
Drug Inactivation by thiol containing species. In the cytoplasm, platinating agents becomes 
aquated, which then enables them to react with thiol-containing molecules, including glutathione 
(GSH) and metallothioneins. Increased concentrations of these compounds are known to induce 
resistance against cisplatin [Siddik Z.H. et al., (2003)].  
Glutathione itself acts as an antioxidant of the cell; it helps to maintain the redox 
environment while maintaining reduced sulfhydryl groups. Cisplatin is detoxified by glutathione 
through adduct formation [Rudin C.M. et al., (2003)]. Several ovarian cell lines known to be 
resistant to cisplatin showed a correlation between the degree of resistance and the levels of 
GSH, likely due to increased d-glutamylcysteine synthetase [Godwin A.K et al., (1992)]. In bladder 
carcinoma cisplatin-resistant, exposure to buthiomine sulfoximine (BSO), an inhibitor of 
glutathione synthesis, resulted in a significant enhancement in cisplatin cytotoxicity [Byun S.S. et 
a., (2005)]. Additionally, indomethacin significantly decreases cellular concentrations of GSH and 
sensitizes bladder carcinoma cells to cisplatin treatment [Byun S.S. et a., (2005)]. However, 
neither of these treatments sensitizes these cells to the level of their parent sensitive strain, 
indicating that glutathione is only one component of cisplatin resistance [Byun S.S. et a., (2005)].  
Thioredoxin (Trx), similar to glutathione, regulates the oxidation reduction environment of 
the cell [Amer ES. J. et al., (2001)] and also, it is involved in the regulation of transcription factors, 
apoptosis, and DNA synthesis, among others. Trx is reduced by thioredoxin reductase (TrxR), 
which involves the oxidation of NADPH [Witte A.B. et al., (2005).]. In clinical samples, Trx levels 
correlate with cisplatin resistance in bladder, prostate, liver, gastic, and colon cancer cells [Amer 
ES. J. et al., (2001)]. No study has shown that glutaredoxin (Grx), the analogous enzyme to TrxR in 
the glutathione system, is inhibited by cisplatin; however, the glutathione-cisplatin adduct (GS-Pt) 
is also able to inhibit both mammalian TrxR1 and Grx [Amer ES. J. et al., (2001)].  
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Metallothioneins (MT) are very low molecular weight proteins comprised of several cysteine 
and aromatic amino acid residues [Siegsmund M.J. et al., (1999)]. MT are thought to be involved 
in controlling levels of copper and zinc, as well as protecting cells from oxidative stress and 
toxicities associated with heavy metals, including copper, cadmium, and zinc [Siegsmund M.J. et 
al., (1999); Toyoda H. et al., (2000)]. High levels of MTII have been described in cisplatin-resistant 
cell lines, and cisplatin-resistant bladder cancer lines exhibit cross resistance to cadmium 
[Siegsmund M.J. et al., (1999)]. Human bladder cancer xenografts [Toyoda H. et al., (2000)] and 
esophageal [Hishikawa Y. et al., (1999)] and transitional cell primary carcinomas [Siu L.L. et al., 
(1998)], that express high levels of MT, exhibit less of a clinical response to cisplatin. In head and 
neck cancers, cisplatin induces metallothionein expression [Muramatsu Y. et al., (2000)], while in 
germ cell and testicular tumors, no relationship between MT and cisplatin was observed [Meijer 
C. et al., (2000)]. Therefore the association of MT levels with cisplatin resistance may be tissue 
specific and may play a minor role depending on the cellular environment. 
Increased repair of platinum-DNA adducts. Alteration in the structure of the DNA molecule, leads 
to cellular DNA damage recognition and repair, resulting in platinum resistance. It appears that 
tumor cells can have intrinsic differences in DNA repair mechanisms when compared with their 
normal counterparts, although alterations may also be acquired. The role that DNA repair 
pathways play in mediating platinum resistance has been studied for many years, first in the 
preclinical, and more recently, in the clinical setting, and this knowledge has been used 
prospectively in the clinical arena [Cobo M. et al., (2007)].  
Platinating agent adduct repair occurs primarily through Nucleotide Excision Repair (NER) 
[Rabik C.A. et al., (2007)]. NER is an ATP-dependent multiprotein complex that recognizes the 
binding induced on DNA by 1,2-intrastrand cross-links, and subsequently excises the DNA that 
includes as 27- to 29-base-pair oligonucleotides. The gap that remains is then filled by DNA 
polymerase [Chaney S.G. and Sancar A. J.; (1996)]. However all three types of intrastrand 
crosslinks (1,2-d(ApG), 1,2-d(GpG), and 1,3-d(GpNpG)) are recognized by the NER mechanism, the 
1,2 intrastrand crosslinks are repaired less efficiently than the 1,3 intrastrand crosslinks, 
supporting the hypothesis that the 1,2 intrastrand crosslinks are the cytotoxic lesion [Zamble D.B. 
et al., (1996); Moggs J.G. et al., (1997)]. The excision repair cross-complementation group 1 
(ERCC1) protein plays a key role in nucleotide excision repair. ERCC1 dimerizes with xeroderma 
pigmentosum complementation group F, and this complex is required for the excision of the 
damaged DNA. One of the most impressive and important successes of cisplatin-based therapy is 
in its role in treating metastatic testicular cancer which has resulted in >90% of patients achieving 
cure [Bosl G.J. and Motzer R.J., (1997)]. Studies of testicular carcinoma cell lines were notable for 
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exquisite cisplatin sensitivity in comparison with cell lines derived from other cancers [Welsh C. et 
al., (2004)]. Further in vitro study showed a deficiency in nucleotide excision repair in these cell 
lines, and in particular, reduced levels of ERCC1 and xeroderma pigmentosum complementation 
group F DNA repair proteins [Welsh C. et al., (2004); Koberle B. et al., (1999)]. This finding has also 
been shown in multiple studies with human ovarian cancer cell lines, including cell lines with 
intrinsic cisplatin resistance which showed increased sensitivity to cisplatin after antisense RNA 
inhibition of ERCC1 [Selvakumaran M. et al., (2003)]. In addition, cell lines that develop resistance 
in vitro after exposure to cisplatin chemotherapy were found to have increased expression of 
ERCC1 [Ferry K.V. et al., (2000)]. 
Mismatch repair (MMR) is a highly conserved, strand-specific repair pathway which follows a 
stepwise process, initiated with the recognition of DNA damage [Kunkel T.A. and Erie D.A., (2005); 
Jascur T. and Boland C.R., (2006)]. The mismatch repair system involves at least five proteins 
(MLH1, MSH2, MSH3, MSH6 and PMS2) and functions as a repair mechanism that needs ATP 
[Fishel R., (2001)]. Platinum complexes interfere with normal MMR activity and prevent a repair 
from being completed. Inability to complete the repair of the DNA damage leads to apoptosis. 
When MMR is deficient, cells can continue to proliferate in spite of DNA damage caused by 
platinating agents, and are thus resistant [Peltomaki P., (2003)] Tumor cells deficient in MMR are 
2-3 fold more resistant to cisplatin treatment compared to cells proficient in MMR [Stojic L. et al., 
(2004)]. Defects in MMR may be inherited, as in the case of hereditary nonpolyposis colorectal 
carcinoma or may occur through epigenetic silencing of an essential MMR gene [Peltomaki P., 
(2003); Suzuki H. et al., (1999); Esteller M., (2000)]. Epigenetic silencing of MMR seems to occur 
most often through Mut L homologue 1 (hMLH1) promoter hypermethylation, as has been shown 
in ovarian, endometrial, gastric, and colorectal carcinoma, among others [Peltomaki P., (2003); 
Geisler J.P. et al., (2003); Bignami M. et al., (2003)]  
2.3 Cisplatin and Mitochondria 
While most investigations of cisplatin cytotoxicity have been focused on interactions between 
cisplatin and nuclear DNA, only approximately 1% of intracellular platinum is bound to nuclear 
DNA, with the great majority of the intracellular drug available to interact with other nucleophilic 
sites on other molecules, including but not limited to phospholipids, cytosolic, cytoskeletal and 
membrane proteins, RNA, and mitochondrial DNA [Fuertes M.A. et al., (2003); Gonzalez V.M. et 
al., (2001)]. 
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Mitochondria are subcellular organelles involved in critical cellular processes, from energy 
production to apoptosis. They are rod-shaped structures that are enclosed within two membranes 
each composed of a phospholipid bilayer. The two membranes are quite distinct in appearance 
and in physico-chemical properties, thus determining the biochemical function of each 
membrane. The inner membrane encloses and convolutes into the mitochondrial matrix, forming 
cristae. This serves to increase the surface of the inner membrane, which carries the main 
enzymatic machinery of oxidative phosphorylation. The outer membrane is a simpler structure, 
containing protein called porins which permit the interchange of molecules such as ions, nutrient 
molecules, ATP and ADP. On contrary, the inner membrane is freely permeable only to oxygen, 
carbon dioxide, and water. Its structure is highly complex and includes all the complexes of the 
electron transport system, the ATP synthetase complex, and transport proteins. The membranes 
create two compartments: the intermembrane space that has an important role in oxidative 
phosphorylation [NelsonD.L and Cox M.M, (2002)]. The oxidative processes of cells use to degrade 
fuel molecules yield NADH and FADH2 which are used as electron donors for the electron 
transport chain. These are the basis of chemiosmotic theory that postulates the coupling of 
respiration and ATP synthesis in mitochondria [Mitchel P., (1965)]. The free energy of electron 
transport is conserved by the proton gradient, which is built up by the enzymatic complexes of 
the electron transport chain. These complexes pump protons from the matrix to the 
intermembrane space and create an electrochemical gradient across the inner membrane. This 
gradient then enables the ATPase to synthesize ATP. The electrochemical gradient, resulting in a 
negative charge within mitochondria, may play a role in the accumulation of positively charged 
cisplatin in this organelle [Cullen K. J. et al., (2007)].  
Mitochondria contain their own DNA (mtDNA) that is transcribed and translated to 
synthesize 13 proteins of the mitochondrial electron transport chain [Fernandez-Silva P. et al. 
(2003)]. Cisplatin may crosslink also mitochondrial DNA that, lacking nucleotide excision repair, is 
significantly more sensitive than nDNA to the damage [Preston T.J. et al., (2001)]. Indeed, 
mitochondria are thought to be a major target for cisplatin in cancer cells [Tacka, K. A. et al., 
(2004)] and alterations in mitochondrial function (reduced mitochondrial respiration and ATP 
production) have been investigated in cancer cell resistance [Harper M. E. et al., (2002)]. Recent 
findings has shown that cells depleted of mtDNA show significant resistance to cell death induced 
by cisplatin [Park S.Y. et al., (2004); Montopoli M. et al., (2009)], confirming that mtDNA is a major 
target of CDDP. 
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Furthermore mitochondrial damage by cisplatin has been increasingly studied as a mediator of 
systemic toxicity such as gastrointestinal toxicity, ototoxicity [Devarajan P. et al., (2002)] and 
nephrotoxicity [Park M.S. et al. (2003)]. 
3. ENERGETIC METABOLISM IN HEALTHY CELLS 
In normal cells a large amount of ATP is required to replicate all cellular contents: glucose 
participates with two ATP molecule synthesis through glycolysis and up to 36 ATPs through its 
complete catabolism by the TCA cycle and OXPHOS (oxidative phosphorylation). The large 
requirements for nucleotides, amino acids, and lipids are provided by intermediate metabolites of 
these pathways. In addition to glucose, glutamine is catabolized in appreciable quantities for most 
mammalian cells growing in culture. Therefore glucose and glutamine both supply carbon, 
nitrogen, free energy, and reducing equivalents necessary to support cell growth and division. 
This means that glucose, in addition to being used for ATP synthesis, should also be diverted to 
macromolecular precursors such as acetyl-CoA for fatty acids, glycolytic intermediates for non-
essential amino acids, and ribose for nucleotides to generate biomass.  
Glycolytic pathway. Glucose enters the cell through glucose transporters (GLUTs) and thereafter it 
is phosphorylated to glucose-6-phosphate (G6P) by hexokinase 2 (HK2). Phosphoglucose 
isomerase catalyzes G6P to fructose-6-phosphate (F6P), which yields fructose-1,6-biphosphate by 
phosphofructokinase 1 (PFK1), and then pyruvate and ATP by pyruvate kinase (PK) in the final step 
of glycolysis. Pyruvate is converted to acetyl-CoA, which enters the TCA cycle. Ultimately, 
glycolysis produces two ATP molecules and six NADH molecules per glucose. In normal tissues, 
most of the pyruvate is directed into the mitochondrion to be converted into acetyl-CoA by the 
action of pyruvate dehydrogenase (PDH) or transaminated to form alanine (Figure 6). 
 
Fig. 6: Metabolic pathways involved 
in glucose metabolism  
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Pentose phosphate pathway (PPP). This is a metabolic pathway that generates NADP and pentose 
sugars from G6P. The enzyme that governs the entry of G6P into this pathway is glucose-6-
phosphate dehydrogenase (G6PD), which is regulated by the availability of its substrate and the 
NADPH to NADP+ ratio [Saiati L.M. and Amir-Ahmady B., (2001)]. G6P is converted to ribose-5-
phosphate (R5P) while producing two molecules of NADPH (Figure 6). NADPH is both a major 
cellular antioxidant, maintaining glutathione in a reduced state to prevent oxidative damage, and 
a required cofactor in the reductive biosynthesis of fatty acids, nucleotides, and amino acids. 
NADH is also used in mitochondrial OXPHOS.  
Tricarboxylic acid (TCA) cycle. Pyruvate produced by glycolysis is converted to acetyl-CoA, which 
enters the TCA cycle, and citrate, α-ketoglutarate, succinyl-CoA, fumarate, malate, and 
oxaloacetate are produced as intermediate products (Figure 7). Most of the carbon for fatty acids 
derives from acetyl-CoA synthesized in the mitochondrial matrix. However, acetyl-CoA cannot 
cross the inner mitochondrial membrane, but intramitochondrial acetyl-CoA and oxaloacetate 
combine to form citrate, which is transported out of the mitochondria and broken back down into 
its constituents by ATP citrate lyase (ACLY). Acetyl-CoA is converted to malonyl-CoA by acetyl-CoA 
carboxylase, and acetyl-CoA and malonyl-CoA are then both used by the multi-subunit enzyme 
fatty acid synthase (FAS) for the synthesis and elongation of fatty acid chains. Oxaloacetate is 
used for the synthesis of non-essential amino acids. Cytosolic and nuclear acetyl-CoA is also a 
precursor for the post-translational modification of proteins (for example, histones) by 
acetylation. Similarly to citrate, malate produced in the TCA cycle leaves the mitochondria, and it 
is converted to pyruvate plus NADPH. Citrate might also be converted to isocitrate and then to α-
ketoglutarate, generating another molecule of NADPH by the action of isocitrate dehydrogenase 1 
(IDH1).  
 
Fig. 7: TCA cycle and glutamine metabolic pathways. 
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Glutaminolysis. After glutamine is taken into the cell, a mitochondrial-associated enzyme, 
glutaminase-1 (GLS), converts it to glutamate. Glutamate is converted to α-ketoglutarate and 
enters the TCA cycle in the mitochondria (Fig. 7). Glutamate can also be converted to aspartate, 
which contributes to nucleotide synthesis. The excessive quantity of glutamine used by the cells 
results in alanine and ammonium secretions. Furthermore glutamine contributes both to the 
substrate needs of a dividing cell and of redox potentials through the NADH synthesis of.  
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4. METABOLIC REPROGRAMMING IN CANCER CELLS 
The uncontrolled cell proliferation that characterizes the essence of neoplastic disease, involves 
not only deregulated control of cell proliferation, but also corresponding adjustment of energy 
metabolism in order to fuel cell growth and division [Hanahan D. and Weinberg R.A.; (2011)]. This 
means that, in contrast to normal cells, cancer cells metabolism appears to be adapted to 
facilitate the up-take and the incorporation of nutrients needed to generate a new cell [Vander 
Heiden M.G. et al., (2009)]. Indeed, several altered oncogenes and tumour suppressor genes, 
directly control and activate metabolic pathways that maintain and enhance an efficient wiring 
between glycolysis, oxidative phosphorylation, the pentose phoshate pathway and glutamine 
metabolism, that allows for both NADPH production and Acetil-CoA flux to the cytosol for lipid 
synthesis [Menedez J.M.; (2010)]. Several important hallmarks of the metabolic reprogramming 
include an increase of protein and DNA synthesis and the functionally relationship between the 
glycolytic pathway and the increased de novo fatty acids synthesis [Kuhajda F.P; (2000)]. By 
shifting from oxidative to glycolytic metabolism cancer cells catabolize glucose at a rate that 
exceeds bioenergetic need [Shaw R.J., (2006); Bui T. and Thompson C.B., (2006)]. In this scenario 
tumor cells can redirect the excess glycolytic intermediates toward the novo fatty acids synthesis 
(Figure 8) [Menendez J.M. and Lupu R., (2007)]. 
 
 
 
 
Fig. 8: Connecting glucose metabolism and fatty acid biosynthesis pathways in tumor cells. 
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4.1 The Warburg Effect 
In the first half of the 20th century Otto Warburg observed that cancer cells exhibited significant 
alterations in energy metabolism and mitochondrial respiration compared to normal cells 
[Warburg O. et al., (1927)] He showed that tumor cells preferentially use glycolysis for ATP 
generation, even in the presence of sufficient oxygen, postulating the shift from OXPHOS to 
glycolysis as a consequence of a respiratory injury (mitochondrial dysfunction) leading to 
increased aerobic fermentation, a critical event for the origin of cancer [Warburg O., (1956)]. 
Since then the Warburg effect has been demonstrated in different types of tumors and the 
increase in glucose uptake through 18F-deoxyglucose positron emission tomography (FDG-PET), 
positively correlated with poor prognosis and higher metabolic potential in clinical setting 
[Gatenby R.A. and Gillies R.J., (2004); Kroemer G. and Pouyssegur J., (2008)], supporting the 
theory that alterations in cellular metabolism may contribute to the malignant phenotype. 
Since the glycolysis generates only 2 ATPs per molecule of glucose, whereas oxidative 
phosphorylation generates up to 36 ATPs upon complete oxidation of one glucose molecule 
(Lehninger A.L. et al., (1993)], there is some debate about the why cancer cells decide to use the 
less efficient glycolysis rather than OXPHOS. One compelling idea is that the altered metabolism 
of cancer cells confers a selective advantage for survival and proliferation in the unique tumor 
microenvironment. Initial work focused on the concept that glycolytic metabolism arises as an 
adaptation to hypoxic conditions during the early avascular phase of tumor development, as it 
allows for ATP production in the absence of oxygen [Guppy M. et al., (1993)]. Another explanation 
is that the high levels of lactic acid produced during glycolysis may activate metallo-proteinases 
and matrix remodeling enzymes, thus promoting cancer invasion and metastasis [Berardi M.J. and 
Fantin V.R., (2011); DeBerardinis R.J. et al., (2008)]. Others proposed that tumor cells develop 
defects in mitochondrial function, and aerobic glycolysis is therefore a necessary adaptation to 
cope with a lack of ATP generation by OXPHOS. However, it was later appreciated that 
mitochondrial defects are rare [Frezza C. and Gottlieb E., (2009)] and that most tumors retain the 
capacity for oxidative phosphorylation and consume oxygen at rates similar to those observed in 
normal tissues [Weinhouse S., (1976)]. Finally it has been proposed that the aerobic glycolysis 
provides a biosynthetic advantage for tumor cells, and that a high flux of substrate through 
glycolysis allows an increased intermediate generation providing building blocks and precursors 
for the synthesis of DNA and fatty acids and for redox regulation [DeBerardinis R.J. et al., (2008); 
Vander H. et al., (2009)]. For instance, glucose6phosphate, the product of the first glycolytic 
reaction, can be channeled to the pentose phosphate pathway (PPP) to generate 
ribose5phosphate and NADPH, key intermediates in nucleotide biosynthesis and in redox 
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homeostasis respectively. NADPH and 3 carbon intermediates are also important for lipid 
biosynthesis. 
It is known that glucose and glutamine supply the carbon, nitrogen, free energy and reducing 
equivalents necessary to support cell growth and division. Thus, in cancer cells there is an 
increasing of glucose uptake that is transported into cells by facilitative transporters and then 
trapped intracellularly by glucose phosphorylation [Berg J.M. et al., (2002)]. The hexose 
phosphate is further phosphorylated and split into three-carbon molecules that are converted to 
glycerol for lipid synthesis or sequentially transformed to pyruvate. Pyruvate in normal cells is 
preferentially converted to acetyl-CoA in the tricarboxylic acid (TCA) cycle, while in cancer cells 
can also be transaminated to alanine or become lactate, particularly under hypoxic conditions. 
Formation of citrate from acetyl-CoA and oxaloacetate permits a new round of TCA cycling, 
generating high-energy electrons, CO2, and carbon skeletons that could be used for biosynthesis 
or anaplerosis. Citrate itself could be extruded into the cytosol and then converted to acetyl-CoA 
by ATP citrate lyase (ACLY) for fatty acid synthesis and generation of biomembranes. Glucose, 
through the pentose phosphate pathway (PPP), generates ribose for nucleic acid synthesis and 
NADPH for reductive biosynthesis. Most of the carbon for fatty acid synthesis is derived from 
glucose, but also glutamine uptake appears to be critical for lipid synthesis in that it supplies 
carbon in the form of mitochondrial oxaloacetate to maintain citrate production in the first step 
of the TCA cycle [Wise D.R. et al., (2011); Metallo C.M. et al., (2012); Mullen A.R. et al. (2012)]. 
Thus, metabolism of both glutamine and glucose is orchestrated to support the production of 
acetyl-CoA and NADPH needed for fatty acid synthesis.  
4.2 Lipogenic Phenotype  
Development and progression of cancer are frequently associated with an increased rate of de 
novo lipid synthesis compared with their normal counterparts [Ookhtens M. et al., (1984); Rashid 
A. et al., (1997)]. This metabolic change occurs as a result of common oncogenic insults and is 
mediated by the activation of multiple lipogenic enzymes. In support of this hypothesis, blockade 
of lipogenesis by chemical inhibitors or RNA interference (RNAi)–mediated silencing of lipogenic 
enzymes or their regulators, attenuate cell proliferation and ultimately lead to cell death [Kinlaw 
W.B. et al., (2006); Pizer E.S. et al., (1996)]. Increased lipids not only supply energy through β-
oxidation, but more importantly serve as precursor of membrane phospholipids, signaling and 
secondary messengers essential for a faster cell proliferation [Swinnen J.V. et al., (2006)]. 
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Although lipogenic phenotype of cancer cells has been primarily attributed to an increased 
expression or aberrant activity of the major lipogenic enzyme fatty acid synthase (FAS) that is 
responsible for the terminal catalytic step in fatty acids synthesis [Kuhajida F.P., (2000); Kuhajida 
F.P., (2006); Swinnen J.V. et al., (2006)], other enzymatic mechanisms are involved. First, the net 
conversion of glucose to lipids is dependent on the ability of cells to produce cytosolic Acetyl-CoA 
from mitochondria-derived citrate trough the action of ATP citrate lyase (ACLY). Markedly 
increased ACLY expression and activity have been reported in cancer cells [Swinnen J.V. et al., 
(2006); Bauer D.E. et al., (2005); Hatzivassiliou G. et al., (2005)]. The relevance of ACLY-driven 
challenging of glucose into de novo lipid synthesis as an important component of cell growth and 
transformation is supported by the fact that ACLY inhibition, drastically limits the in vitro 
proliferation [Bauer D.E. et al., (2005)] and reduces tumorigenesis in vivo [Hatzivassiliou G. et al., 
(2005)]. Second, CoA carboxylase (ACACA), the rate limiting enzyme for the long Fas synthesis that 
catalyses the ATP-dependent carboxylation of Acetyl-CoA to malonil-CoA [Tong L., (2005)], has 
been shown to be overexpressed both at mRNA and protein levels, not only in advanced breast 
carcinomas, but also in preneoplastic lesions associate with increased risk for the development of 
infiltrating breast cancer [Milgraum L.Z. et al., (1997)]. 
4.3 Key Regulators of the Metabolic Reprogramming 
Research over several decades has identified many oncogenes and tumor suppressors that are 
involved in the metabolic switch from OXPHOS toward an altered glycolysis of tumor cells. A 
substantial proportion of these oncogenes have been shown to stimulate genes encoding for 
proteins that mediate glycolysis and glutaminolysis.  
AKT. The serine/threonine kinase AKT, a downstream effector of the insulin signaling, plays a 
major role in cell survival and proliferation and is an important promoter of glysolysis. In the 
majority of tumor cells, Akt is hyperactive and seems to drive addiction to glucose metabolism for 
survival and proliferation [Elstrom R.L. et al., (2004)]. The Akt glycolytic enhancer role is driven by 
stimulation of glucose uptake in response to insulin [Elstrom R.L. et al., (2004)]. Akt upregulates 
GLUT1 by enhancing its expression at transcription level. Moreover the AKT signaling enhances 
glucose metabolism within the cell by stimulating the association of HKII with the mitochondrial 
outer membrane, thus positioning it to phosphorylate glucose to glucose6phosphate for use in 
glycolysis and other metabolic pathways [Pastorino J.G. et al., (2005)]. Akt’s ability to promote 
metabolism via glycolysis is also partly due to induced expression of glycolytic enzymes through 
the mTOR and HIF1 signaling [Hay N., (2004)].  
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mTOR. The mammalian target of rapamycin (mTOR) is an energy censor that promotes nutrient 
uptake and glycolysis. Deregulation of mTOR pathway is often found in cancer cells [Chapuis N. et 
al., (2010)]. Under nutrient deprivation, mTOR forms a stable complex with raptor, leading to an 
inhibition of mTOR kinase activity [Kim D.H. et al., (2002)]. Akt regulates mTOR through the 
inactivation of the protein tuberous sclerosis2 (TSC2). TSC2 and TSC1 associate and form a 
complex that suppresses mTOR activity [Crino P.B. et al., (2003)]. Activated AKT phosphorylates 
TSC2, thus affecting its interaction with the small G protein Rheb, which when loaded with GTP, 
activates mTORC1 [Kim D.H. et al., (2002); Inoki K. et al., (2002)]. The activation of mTORC1 
increases glycolysis by increasing the translation of the mRNA encoding HIF-1α thus stimulating 
the expression of glycolytic enzymes [Duvel K. et al., (2010)]. Importantly, mTOR is regulated by 
liver kinase B1 (LKB1) and AMPK [Green A.S., et al., (2011)]. The mTOR energy sensor function is 
conferred in part by AMPK, a heterotrimeric serine/threonine kinase consisting of a catalytic 
subumit (α) and two regulatory subunits (β and Ƴ) [Carling D. et al., (2008)]. Nutrient depravation 
causes cellular stress, leading to an increase of the AMP/ATP ratio, which promotes the binding of 
AMP to the Ƴ regulatory subunit and triggers AMPK activation [Luo Z. et al., (2010)]. AMPK 
activation in turn induces TSC2 phosphorylation, leading to suppression of mTOR activity and 
inhibition of protein translation. The serine/threonine kinase LKB1 activates AMPK under low ATP 
conditions [Shackelford D.B. and Shaw R.J., (2009)]. Therefore, the LKB1/AMPK/mTOR axis serves 
as an important energy sensor that links energy status and the metabolic signaling pathways 
[Scholl C. et al., (2008)].  
HIF. Hypoxia inducible factor 1, is an heterodimer protein complex that consists of HIF-1α and HIF-
1β, has been implicated in the induction of key genes involved in cell proliferation, oxygen and 
nutrient delivery, and anaerobic energy metabolism [Patiar S. and Harris A.L., (2006)]. HIF-1α is 
degradated in normoxia: oxygen promotes prolyl hydroxylation, which stimulates the association 
of HIF-1α with the Von Hippel-Linau (VHL) tumor suppressor, thereby targeting HIF-1α for 
ubiquitination and proteosomal degradation. Hypoxia suppresses prolyl hydroxylation through a 
process involving mitochondria generated ROS [Brunelle J.K. Et al., (2005); Mansfield K.D. et al., 
(2005)]. HIF-1 α has been found highly expressed within hypoxic tumors and at low levels within 
normal tissue [Semenza G.L., (2003)]. As such, HIF-1 is considered as the master sensor that 
orchestrates cellular responses to changes in oxygen homeostasis: HIF-1 upregulates 9 of the 10 
genes involved in glycolysis and, thus, plays a key role in switching glucose metabolism from 
OXPHOS to glycolysis when cells are in a hypoxic environment [Semenza G.L., (2003); Macheda 
M.L. and Rogers S. (2005)]. HIF promotes: 1) glucose uptake by upregulating the expression of the 
GLUT1; 2) glucose metabolism by upregulating hexokinase, the enzyme responsible of the first 
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glycolytic reaction; 3) LDHA expression [Pouyssegur J. et al., (2006); Semenza G.L., (2007)]; 4) 
upregulates PDK1 thus preventing the use of pyruvate by the mitochondria [Papandreou I. et al., 
(2006)]. HIF-1 expression is regulated by molecules such as FH and SDH: loss of function 
mutations of FH and SH lead to the accumulation of fumarate and succinate TCA cycle 
intermediates, resulting in inhibition of the α-ketoglutarate-dependent prolyl hydroxylase, 
thereby stabilizing HIF1 [Gottlieb E. and Tomlinson I.P., (2005)]. 
c-MYC. This oncogene affects many cellular functions including energy metabolism [Dang C.V. et 
al., (2009)]. c-Myc overexpression is estimated to be associated with at least 40% of all cancers 
[Wokolorczyk D. et al., (2008)]. Similar to HIF-1, c-Myc promotes glycolysis mainly through 
upregulation of glycolytic molecules including GLUT1, HKII, phosphofructokinase (PFK), enolase, 
and LDH [Bensaad K. et al., (2009)]. c-Myc also plays a major role in promoting glutamine use in 
cancer cells through the upregulation of glutamine transporters SLC5A1and SLC7A1 and of GLS1 
by repressing the expression of miR-23A and miR-23B thus releasing the suppressive effect of 
these miRNAs on GLS1 expression.  
p53. The tumor suppressor p53 is a stress sensor and cell cycle checkpoint regulator in 
mammalian cells that plays essential roles in cell cycle regulation, apoptosis, and genome stability 
[Aylon Y. and Oren M., (2007)]. The role of p53 in energy metabolism was recognized by Matoba 
et al. [Matoba S. et al., (2006)], demonstrating that loss of p53 diminishes the synthesis of 
cytochrome C oxidase, a nuclear DNA encoding gene whose product is necessary for the assembly 
of mitochondrial respiratory complex IV. Thus, this study directly links p53 to OXPHOS. The loss of 
p53 shifts the cellular ATP production from mitochondrial respiration to glycolysis. Moreover, 53 
protein represses the expression of the GLUT1 and GLUT4 transporters. Thus, the loss of p53 
enhances the expression of glucose transporters and further promotes glycolysis. Interestingly, 
Benssad et al. identified a p53 target gene known as TP53 induced glycolysis and apoptosis 
regulator (TIGAR), which is a potent glycolysis regulator [Bensaad K. et al., (2006)]. Expression of 
TIGAR decreases the intracellular level of fructose2,6-bisphosphate, which otherwise suppresses 
glycolysis by shunting glucose to the PPP [Chesney J. et al., (1999)] . In addition, p53 also affects 
energy metabolism by regulating AMPK, mTOR, PTEN, and IGF binding protein3 [Feng Z. and 
Levine A.J., (2010)]. 
Ras. Ras mutations are found in approximately 30% of all human cancers [Bos J.L., (1989)] and are 
important in promoting cancer initiation and progression [Friday B.B. and Adjei A.A., (2005)]. K-
The most commonly mutated oncogenic Ras in pancreatic cancer, has been shown to affect the 
shape and function of the mitochondria during fibroblast transformation [Chiaradonna F. et al., 
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(2006)]. Further studies showed that fibroblasts transformed by K-Ras activated attenuated 
OXPHOS by suppressing the activity of respiratory complex I, with a corresponding decrease in the 
expression level of complex I proteins [Baracca A. et al., (2010)]. Similarly, H-Ras transformed 
mouse fibroblasts exhibited low mitochondrial respiration, an increased dependency on 
glycolysis, a sensitivity to glycolytic inhibitors, and an insensitivity to OXPHOS inhibitors [Yang D. 
et al., (2010)]. However, K-Ras may affect the synthesis of the mitochondrial phospholipid 
cardiolipin and that the absence of led to K-Ras increased respiration [Chun S.Y. et al., (2010)], 
suggesting that the effect of K-Ras on mitochondrial respiration is likely complex and requires 
further study. 
5. TRANSMITOCHONDRIAL HYBRIDS 
Cancer cells adapt themselves to hypoxic and acidic conditions generated during progressive 
tumor cell growth by shifting the burden of energy metabolism from mitochondrial oxidative 
phosphorylation to glycolysis [Gatenby R.A. and Gillies R.J. (2004)] and it is not surprising that 
mitochondria might play a crucial role in this transition.  
Mitochondria are multifunctional organelles that regulate metabolism, cellular energy 
production and cell death pathways, and are involved in free radical production. Human 
mitochondria contain their own circular DNA (mtDNA) that consists of 16,569 bp and encodes 13 
oxidative phosphorylation (OXPHOS) subunits, 22 transfer RNAs (tRNAs), 2 ribosomal RNAs 
(rRNAs) and the displacement loop (D-Loop) [Taanman J.W., (1999)]. The remaining subunits of 
OXPHOS complexes are encoded by nuclear DNA and imported into the mitochondria. mtDNA is 
present as thousands of copies per cell and is not associated with histones. Because it is not 
protected by histones and due to its close proximity to reactive oxygen species (ROS) production, 
mtDNA is directly exposed to the damaging effects of ROS produced during OXPHOS. Additionally, 
because of a limited DNA repair system, mtDNA has a higher mutation rate than nuclear DNA. The 
effect of mtDNA in tumorigenesis or progression to malignancy can be achieved through a 
number of changes in mtDNA; first of all, by reducing the mtDNA content [Kulawiec M. et al., 
(2008)] Indeed, tumor-specific changes in the mtDNA copy number have been reported in human 
cancers. Reduced mtDNA content has been reported in breast [ Yu M. et al., (2007); Mambo E. et 
al., (2005); Tseng L.M. et al., (2006)] prostate [Mizumachi T. et al., (2008) ovarian[Desouki M.M. et 
al., (2005)], renal [Selvanayagam P. and Rajaraman S., (1996)]; hepatocellular carcinoma [Lee H.C. 
et al., (2005); Yin PH. Et al., (2004)] and in gastric tumors [Wu C.W. et al., (2005)]. The second type 
of change through which tumorigenesis can be achieved is a decrease in mitochondrial gene 
expression [Weber K. et al., (2002)] or alteration in mitochondrial enzymatic activity [Espineda 
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C.E. et al., (2004);. Isidoro A. et al., (2004)]. The third type of change in mtDNA is somatic or germ 
line mtDNA mutations. However, a majority of these somatic mtDNA changes are in the 
noncoding D-loop regions or result in silent amino acid changes, that do not apparently affect 
mitochondrial function. Only a few mtDNA may harbor identifiable pathogenic mutations. In 
order to investigate the role of mitochondria and their involvement in the pathogenic 
mechanisms of cancer development, the effect of nuclear background must be excluded 
[Krishnamachary B. et al., (2003); Ohta S., (2006)] and transmitochondrial hybrids, generated by 
fusion of enucleated cell with cells deprived of mitochondria, represent an useful experimental 
model.  
The technique of cytoplasts fusion with whole cells (Fig. 9) is based on the creation of 
mtDNA-depleted cells () through prolonged treatment with 3.8-diamino-5-ethyl-6-
fenilfenantridiniombromuro or ethidium bromide (EtBr) [King M.P. and Attardi G., (1989); King 
MP and Attardi G., (1996)]. EtBr is an intercalating agent selectively toxic for mtDNA that, 
differently from nDNA, hasn't efficient DNA repair systems [Goldring E.S., et al., (1970); Nagley P. 
and Ninnane A.W. (1970)].  
EtBr
Recipient cell Donor cell
 
 
 
The  cells derived from this step, are mtDNA-deficient and consequently their mitochondria are 
completely non-functional, nevertheless, they can survive by adding to the culture medium 
supplements ensuring a sufficient support of energy. Theoretically it is possible to create  from 
any cell line; in practice 206- coming from the line TK--143B are the most commonly used 
mtDNA deficient cells to create transmitochondrial hybrids. TK- refers to the lack of the thymidine 
kinase enzyme normally deputy to the synthesis of thymidine monophosphate from thymidine. 
After checking that  cells are completely devoid of mtDNA,  are fused with vesicles containing 
Fig. 9: cytoplasts fusion with whole cells 
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mitochondria from a donor cell. The fusion is, mediated by polyethylene glycol 1500 (PEG). The 
advantage of this experimental model is the fact that it allows to analyze different mtDNA in a 
nuclear DNA environment virtually identical, without any influence of their own nuclear DNA. 
It has been shown that 206- cells are dependent from addition of uridine and pyruvate in 
the culture medium [King M.P. and Attardi G., (1996)]. The uridine dependence is due to the fact 
that the diidrooratato dehydrogenase enzyme, involved in the pyrimidines biosynthetic pathway, 
is localized in the inner mitochondrial membrane and its activity thus dependents from the 
membrane potential. In  cells the potential is not present, and then the enzyme is inactive. 
Therefore it is necessary to provide a pyrimidine precursor in the form of Uridine. Instead, the 
pyruvate dependence, is an unexpected phenomenon. Indeed, the  cells should be able to 
generate large amounts of pyruvate from glucose metabolism through the glycolytic pathway. 
The most widely accepted hypothesis is that the lack of the respiratory chain functionality 
prevents the oxidation of NADH produced in the cytoplasm, so the pyruvate reduction to lactic 
acid may be a way to elimenate the excess of NADH cytosolic. This would reduce the amount of 
pyruvate available to enter the tricarboxylic acid cycle (TCA) leading to the need of pyruvate 
addition. 
According to the method of cybrids creation, after the merger, a long period of selections 
using the appropriate medium is necessary. The selection serves to eliminate from cell culture:  
cells who have not acquired mitochondria; donor cells; and residual cells that have acquired also 
the nuclear DNA (binucleate hybrids). Donor cells and hybrids binucleate can be removed using 
bromodeoxyuridine (BrdU) in the culture medium. This compound is an analogue of thymidine 
and therefore is recognized by the enzyme thymidine kinase and subsequently used in the 
synthesis of DNA creating lethal mutations. The cells TK- ( and cybrids) are not able to process 
the BrdU then that is not incorporated into DNA. By contrast, donor cells and binucleate hybrids 
possess at least one copy of the enzyme thymidine kinase, thus will be killed by the presence of 
BrdU. To delete  cells, their dependence from uridine and pyruvates has been exploited. 
Therefore, a free uridine and pyruvate/DMEM, added with fetal serum dialyzed to 5%, was used. 
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AIM 
The complex regulatory networks involving cancer genes and metabolic pathways need to be 
defined for specific cancer types so that the targeting of cancer cell metabolism could be 
strategically focused for specific genetic changes of particular cancers.The major goal of this 
investigation was to gain insights into the relevant processes and/or compensatory mechanisms 
that turn energetic metabolism specifically in cisplatin-resistant cancer, a phenomenon with 
clinical implications in chemotherapy. To this aim, we used a combination of genetics, 
biochemistry and metabolomics to identify different signatures of metabolic adaptations 
operating in cisplatin-sensitive (2008) and cisplatin-resistant (C13) human ovarian cancer cells. 
Mitochondria was studied using trans-mitochondrial hybrids derived from 2008 and C13 cells to 
establish the contribution of mitochondrial and nuclear DNA in cisplatin-resistance. More in 
detail, we aimed to identify, in the metabolomic fingerprint of cisplatin-resistant cells, possible 
targets useful to design pharmacological strategies to bypass the resistance. 
The results generated will potentially lead to novel prognostic and predictive biomarkers for 
chemosensitization and/or novel therapeutic strategies for tumours resistant to cisplatin. 
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MATERIALS AND METHODS 
1. Cell lines 
1.1 Human ovarian carcinoma cell lines  
2008 (wild type) and C13 (cisplatin-resistant) were grown in RPMI 1640 medium supplemented 
with 10% fetal bovine serum, 4 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 
in humidified condition at 5% CO2 and 37° C. Cells were collected every 2 days with minimum 
amount of 0.25% trypsin-0.2% EDTA and seeded at 2x106 density in 100mm dishes.  
1.2 206-ρ° cell line 
206-ρ° cells, obtained from mtDNA depletion of 143B-TK- osteosarcoma cells, were cultured in 
high-glucose Dulbecco's modified Eagle's medium (Gibco), supplemented with 10% fetal bovine 
serum (FBS), mm L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 1mM sodium-
pyruvate, 1 % of a solution of not essential aminoacid (NEAA) and 0.05 mg/ml uridine in 
humidified condition at 5% CO2 and 37° C. 
1.3 Transmitochondrial cybrid cell lines  
H2008 and HC13 were generated by polyethylene glycol fusion of enucleated 2008 and C13 with 
the mtDNA-less (ρ0) osteosarcoma (143B.TK-) cell line (kind gift of Andrea Martinuzzi) as 
previously described (King and Attardi, 1989). After fusion the cells were replated 24 hours in 
uridine-free DMEM supplemented with 100 µg/ml BrdU and 10% dialyzed FBS to allow selection 
of hybrids. Individual hybrid clones were isolated 10–20 days later using glass cylinders. Hybrid 
cell lines (H2008 and HC13) were cultured in high-glucose Dulbecco's modified Eagle's medium 
(DMEM, Cambrex-Lonza, NY, USA), supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 1mM sodium-pyruvate and 1 % of a 
solution of not essential aminoacid (NEAA), in a humidified atmosphere of 95% air and 5% CO2 at 
37°C. 
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2. Cell viability assays 
2.1. MTT assay 
MTT test, first described by Mosmann in 1983, is based on the ability of mitochondrial 
dehydrogenase enzyme from viable cells to reduce the tetrazolium ring of the pale yellow MTT [3-
[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide into the dark blue formazan crystals. 
For the assay, 2500 cells/well were seeded in 96-well plates, allowed to attach overnight and 
exposed at different concentrations (0.1-100 μM) of cisplatin (Teva, Italy). After 24 hours 20 
μL/well of a 5 mg/ml MTT solution (Sigma-Aldrich, St Louis, MO, USA) was added and cells 
incubated for 4 hrs at 37°C. The formazan crystals were dissolved by adding 200 μl of acidic 
isopropanol and the absorbance (Abs) was measured at 570 nm using a Victor3X multilabel plate 
counter (Wallac Instruments, Turku, Finland). CDDP IC50 values were extrapolated from 
concentration-response curves, calculated as the concentration causing a 50% reduction of Abs in 
comparison with untreated cells. 
2.2 Trypan blue exclusion assay  
This test measures the percentage of viable cells with the intact membrane thus excluding the 
blue dye, while dead cells take up the colouring agent. 6 wells plates were seeded with a constant 
number of cells and, following overnight incubation, were exposed to different treatments, 
according to experimental protocols. At the end of incubation the cells were washed, detached 
with 0.25% trypsin-0.2% EDTA and suspended in trypan blue (Sigma-Aldrich, St Louis, MO, USA), 
at 1:1 ratio in medium solution. Cell number was counted using a chamber Burker 
hemocytometer under the microscope. 
2.3 Annexin V/propidium iodide staining.  
Annexin V, belonging to the annexin proteins with anticoaugulant properties, has proven to be an 
useful tool in detecting apoptotic cells since, in the presence of Ca2+, it preferentially binds to the 
negatively charged phospolipids like PS (phosphatidylserine). Phosphatidylserine is normally 
located on the cytosolic surface of the plasma membrane, but, in early apoptotic cells, it 
translocates to the extracellular surface to be recognised and phagocytised by macrophages.  
Cells were seeded in 12 wells-plates, incubated overnight and treated with different 
concentrations of CDDP (1-10 μM). After 24 hrs of incubation cells were harvested by quick 
trypsinization and centrifugated at 1200 rpm for 5 minutes. The cell pellet was resuspended in 56 
μL of a binding buffer *10 mM HEPES (Sigma-Aldrich), 140 mM NaCl; 2,5 mM CaCl2 ; H2O q.b.] 
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containing 80 nM of Alexa Fluor 488 annexin V and 33 μM of propidium iodide (PI) (Molecular 
Probes, Invitrogen, Carlsbad, CA, USA). The samples were incubated for 15 minutes at room 
temperature in the dark and, after dilution with the binding buffer, the fluorescence of stained 
cells was analysed by Epics XL flow cytometer (Coulter Systems, Fullerton, CA, USA) at laser 
excitation of 488 nm. The green emission signal of Annexin V was measured at 525 nm and the 
red emission signal of PI at 620 nm. The cell population separates into three groups: viable live 
cells show almost a negative fluorescence for both annexin V and PI, apoptotic cells show green 
fluorescence (Annexin V+/PI–), and dead cells show both red and green fluorescence (Annexin 
V+/PI+). 
3. ATP-luciferase assay  
Cells were seeded in 12 wells-plate, incubated overnight and treated according to the 
experimental protocols. After 24 hrs ATP levels were measured using the Luminescence ATP 
Detection Assay System (PerkinElmer) that is a bioluminescence assay for quantitative 
determination of ATP with recombinant firefly luciferase and its substrate D-luciferin. The assay is 
based on luciferase’s absolute requirement for ATP in producing light (emission maximum ~560 
nm at pH 7.8). The luminescence was read with VictorTM X3 multilabel reader (Wallac Instruments, 
Turku, Finland) and normalized on the protein content of each sample. 
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4. Oxygen consumption  
Oxygen consumption was measured in live cells (3.5x106) incubated in 1 ml glucose-free DMEM 
(Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% Na-pyruvate (Cambrex-Lonza, NY, 
USA) at 37°C, using a Clark-type oxygen electrode (Hansatech Instruments, King's Lynn, Norfolk, 
UK). Using the software Oxygraph plus v. 1.01 the oxygen consumption is detected by the time: 
 
Data processing includes: 
Fmol/c/min= (RATE/3.5x106)*1 million 
Where: 
fmol/c/min= femto moles of oxygen consumed by one cell every minute 
RATE= slope of the curve of a range of one minute 
3.5x106= number of cells 
5. Mitochondrial membrane potential (ΔΨ) and mitochondrial mass  
5.1 Flow ytometry 
Mitochondrial transmembrane potential (ΔΨm) was probed by the cationic lipophilic, green-
fluorescent rhodamine-123 (Rh123) (Molecular Probes, Invitrogen, Carlsbad, CA, USA) that is 
readily sequestered by active mitochondria in a potential-dependent manner: a loss of ΔΨm is 
associated with a lack of Rh123 retention and a decrease in fluorescence.  
rate 
1 min 
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Mitochondrial mass was measured by Acridine Orange 10-Nonyl bromide (NAO) staining. NAO is a 
fluorescent probe that selectively binds to cardiolipin (CL) of mitochondrial membrane regardless 
of mitochondrial membrane potential determining mitochondrial mass. 
Cells were seeded and incubated for 48 hours, washed with phosphate buffer saline solution 
(PBS), detached with 0.25% trypsin-0.2% EDTA and centrifuged for 5 min at 1200xrpm. The cell 
pellet was then resuspended with Rh123 (10 µM) or NAO (25 nM) and incubated for 15 minutes in 
dark. Fluorescence intensity was analyzed using an Epics XL flow cytometer (Coulter Systems, 
Fullerton, CA, USA) equipped with a 488 Argon laser. The green emission signal of Rh123 was 
measured at 525 nm and the orange emission signal of NAO at 580 nm. Necrotic cells were 
excluded by electronically gating data on the basis of forward versus side scatter profiles; a 
minimum of 104 cells of interest were analyzed further. Mean fluorescence intensity (MFI) values 
were obtained using the EXPO 32 software (Coulter Systems, Fullerton, CA, USA). 
5.2 In live cells confocal microscopy 
Cells were grown in 3.5 cm glass-bottom dishes (MatTek coprporation, Ashland, USA) and, after 
24 hrs, were loaded with 100 nmol/L Mitotracker Green(MTG; Invitrogen) and 10 nmol/L 
Tetramethyl Rhodamine Methyl Ester (TMRM; Invitrogen) for 30 minutes. Cells were imaged using 
a laser scanner microscope (Leica TCS SP5, 60X magnification). A volumetric reconstruction was 
then obtained using the software Volocity and the MTG volume was used as a reference volume 
over imposed to the red channel for calculation of the TMRM volume’s intensity. A ratio between 
the two intensities was then provided as a read-out of mitochondrial potential. 10 μmol/L 
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) was used as positive control. 
6. Mitochondrial DNA analysis 
6.1 qRT-PCR 
Total DNA was isolated by Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). 
Evaluation of mitochondrial DNA copy number by quantitative real-time polymerase chain 
reaction (PCR) was performed as previously described [Mussini et al., 2005]. Briefly, a 
mitochondrial DNA fragment (nt 4625–4714) and a nuclear DNA fragment (FasL gene) were co-
amplified by using TaqMan® probe system and Platinum® Quantitative PCR SuperMix-UDG 
(Invitrogen, Life Technologies, Carlsbad, CA, USA). With each assay, a standard curve for 
mitochondrial and nuclear DNA was generated using serial known dilutions of a vector (a kind gift 
from Dr Andrea Cossarizza) in which the regions used as template for the two amplifications were 
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cloned tail to tail to have a ratio of 1:1 of the reference molecules. The absolute mitochondrial 
DNA copy number per cell was obtained by the ratio of mitochondrial to nuclear DNA values 
multiplied by two (as two copies of the nuclear gene are present in a cell). PCR was carried out in 
an iCycler Thermal cycler (BioRad, Hercules, CA, USA) and at least three measurements were 
obtained for each sample. 
6.2. Genome sequences 
The entire mitochondrial genome was sequenced in a series of overlapping fragments using M13-
tagged oligodeoxynucleotide primers to facilitate direct sequencing of the PCR amplified products 
with BigDye terminator chemistries on an Applied Biosystem 3100 automated sequencer 
(Applied Biosystems, Warrington, UK) [Tuppen, 2010]. All sequences were directly compared to 
the revised Cambridge reference sequence for human mtDNA (GenBank Accession number 
NC_012920).  
7. 1H-NMR spectroscopy 
Cells were harvested by trypsinization 0.05% trypsin-0.02% EDTA (CAMBREX), washed in PBS and 
centrifuged for 3 min at 425xg and washed once with PBS. A cell pellet of about 2 x 107 cells was 
resuspended in 500 µl of PBS-D2O in the presence of 0.1% TSP (2,2'-3,3'-tetradeutero-trimethyl-
sylilpropionate sodium salt (Sigma), used as an external chemical shift reference at 0.00 ppm. This 
volume of cells was enough to fill the sensitive volume of the observation coil in the 5-mm probe. 
1H-NMR spectra were recorded on a BRUKER AVANCE DMX-600spectrometer operating at the 
frequency of 600 MHz in the proton dimension, at 298 K. Spectra were acquired with a pulse-and-
acquire sequence (90° pulse of 11.2 μs). Intensity of the residual water signal was reduced by the 
WATERGATE field gradient-based sequence. The total delay between pulses was set to 6 s to 
allow for full relaxation of the interesting metabolites. Data were acquired over a 8000 Hz sweep 
width and digitized with 16K data points. Final spectra were the result of the accumulation of 128 
scans with a total acquisition time of around 14 min. The whole experiment, cell preparation and 
NMR spectroscopy, lasted 60–75 min after the addition of PBS to the cell culture flasks before 
trypsinization. Cell viability, as measured by trypan blue exclusion, was always above 95% after 
trypsinization and above 80% after NMR spectroscopy.  
Spectra were processed using the Bruker Software XWINNMR. The measured FIDs were 
zero-filled to 32 K and Fourier-transformed without apodization. The spectra were manually 
phase-corrected and finally a baseline correction was applied. The signals of the 1D NMR spectra 
were quantified by resonance deconvolution, using the DMFIT5 program. Peaks areas have been 
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normalised to the peak area of polypeptide CH3 signal at 0.94 ppm. Homonuclear two-
dimensional total correlation spectroscopy (TOCSY) experiments were recorded over a spectral 
width of 8000 Hz, as a matrix of 1024X256 data points by summing 32 scans for each increment in 
t1. A repetition time of 1 s was used. Suppression of water signal was obtained by the 
WATERGATE sequence. TOCSY experiments were acquired with a spin-lock period of 70 ms 
achieved with the MLEV17 pulse scheme. The measurement time for the 2D spectra was around 2 
hours. Prior to Fourier transformation the data matrices were zero-filled to 2048X1024 points and 
multiplied for Lorentian-Gaussian and shifted squared sine bell functions in t2 and t1 respectively.  
8. Lipid droplet content  
Nile red (also known as Nile blue oxazone) is a lipophilic stain produced by boiling a solution of 
Nile blue with sulfuric acid. It is used to localize and quantitate lipids, particularly neutral lipid 
droplets within cells. The fluorescence of the dye is heavily dependent on the solvent used: in 
most polar solvents Nile Red will not fluoresce, however when in a lipid-rich environment can be 
intensely fluorescent, with varying colours from deep red to strong yellow-gold emission.  
For the experiment it was prepared a stock solution of Nile red in acetone (500 μg/mL) and the 
fluorescence intensity was measured both by cytometry and microscopy. Nile red fluorescence 
intensity was measured both by cytometry and confocal microscopy. 
8.1 Flow cytometer 
Multiwells plate were seeded with a constant number of cells and, following overnight incubation, 
cells were stained with 1 μmol/L Nile red for 15 minutes. After detachment, cells were 
resuspended in 300 μl of PBS, 2% FBS and 0.02% sodium azide buffer and the fluorescence 
intensity was analysed by Epics XL flow cytometer (Coulter Systems, Fullerton, CA, USA) at laser 
excitation of 488 nm. The yellow signal emission from Nile red was measured at >528 nm.  
8.2. Confocal microscope 
Cells were seeded at approximately 30% confluence on glass cover slips and incubated overnight. 
After 24h, cells were fixed with 4% formaldehyde (SIGMA St Louis, USA) for 15 min, permeabilized 
with 0.1% of Triton for 5 min and stained with 1 μmol/L Nile red and 0.33 μM phalloidin in growth 
medium (SIGMA-ALDRICH) for 1 hrs. After repeated washings, Mowiol 40-88 (Sigma, St Louis, MO) 
was added at a final concentration of 0.5 μg/ml and the slides were examined by fluorescence 
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laser scanning microscope (Nikon C1 confocal microscope and Nikon EZ-C1 software (version 
2.10), magnification 60X). 
9. Immunoblot assay 
Cells were plated in 100 mm cell culture dish and allowed to attach overnight. After 24 hrs cells 
were washed 3 times with PBS and lysed with ice-cold lysis buffer [TRIS 25 mM pH 7,4; NaCl 150 
mM; IGEPAL 1%; sodium deoxycholate 1%; SDS 0,1%; EDTA 1 mM] supplemented with the 
protease inhibitor cocktails (Protease Inhibitor cocktail tablets EDTA-free, Roche Molecular 
Biochemicals, Mannheim, Germany). Cell lysates were then centrifuged at 14000 g for 15 minutes 
at 4°C and the supernatant protein content was determined by Lowry procedure (Bio-rad DC 
Protein Assay) using bovine serum albumin as standard. Laemmli buffer 5X [250 mM Tris-HCl 
pH=6.8, 50% glycerol, 10% SDS, 500 mM β-mercaptoethanol, 0.004% bromophenol blue, H2O q.b] 
was added (1/5 v/v) to protein lysates, and the samples were denatured for 5 min at 100°C. Equal 
amounts of protein (40 µg) were loaded on a 8% polyacrylamide gel and electrophoretically 
separated in running buffer [25 Mm TRIS, 250 mM glicina (Applichem), 0.1% SDS, H2O q.b.], for 1h 
at a constant current of 200 V (Bio-rad Mini-PROTEAN® Tetra System). A molecular weights 
marker was used (Full Range Rainbow Molecular Weight Markers, Amersham Biosciences). After 
electrophoresis, the proteins were blotted onto an Hybond-P PVDF membrane (Amersham 
Biosciences), previously soaked in methanol, using a transfer buffer [25 mM Tris,192 mM glicina, 
H2O q.b.]. A current of 250 mA was applied for 1h and 45min at 4°C. Non specific binding sites 
were blocked by immersing the membrane in TBS-Tween 20 solution containing 10% non-fat 
dried milk and shaking for 1h at room temperature. After 3x10 min washes with TBS-Tween 20 
[10 mM TRIS, 150 mM NaCl, 0,1% Tween 20 (Sigma-Aldrich), H2O q.b.] at room temperature, the 
membrane was exposed to the primary anti-HIF-1α antibody (1:1000; Santa Cruz Biotechnology) 
overnight at 4°C. After washing, the membrane was incubated with HRP-conjugated anti-mouse 
secondary antibody (1:10000; Dako), for 2h at room temperature. The signal was visualized with 
enhanced chemiluminescent kit (Amersham Biosciences) according to the manufacturer’s 
instructions and analyzed by Molecular Imager VersaDoc MP 4000 (Bio-rad). The integrated 
intensity was normalized to beta-actin (1:5000; AbCam). 
10. qRT-PCR analysis 
Cells were grown as indicated and total mRNA was isolated as per manufacturer’s instructions 
using QIAshredder and RNEasy kits (Qiagen) and measured with a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE, USA). 0,5 μg of total mRNA 
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was reverse-transcribed to complementary DNA using The High Capacity cDNA Reverse 
Transcription Kits of Applied biosystem by life technologies [10X RT Buffer, 10X RT random 
Primers, 25X dNTP Mix (100mM), MultiScribe reverse Transcriptase (50U/µL)]. Relative expression 
of each gene was determined by quantitative real-time PCR (StepOne™ Systems of Applied 
biosystem by life technologies) using Power SYBR® Green PCR Master Mix (Applied biosystem by 
life technologies) and the primers designed as follow: GLUT1: 5’: gaccctgcacctcattgg, 3’: 
gatgctcagataggacatccaag; BNIP3: 5’ gaatttctgaaagttttccttcca, 3’ ttgtcagacgccttccaata; LDHA: 5’ 
cgccctctgctcttgattt, 3’ catcacccagagccctacag, MYC: 5’ gctgcttagacgctggattt, 3’ taacgttgaggggcatcg; 
HIF-β (ARNT): 5’ ctacccgctcaggcttttc, 3’ caccaaactgggaagtacgag; PGK1: 5’ cagctgctgggtctgtcat, 3’ 
gctggctcggctttaacc; PFKM: 5’ gccatcagcctttgacaga, 3’ ctccaaaagtgccatcactg. qRT-PCR was 
performed in quadruple using 1 μl of complementary DNA template in a 20-μl reaction. Linearity 
and efficiency of PCR amplifications were assessed using standard curves generated by serial 
dilution of complementary DNA; melt-curve analysis was used to confirm the specificity of 
amplification and absence of primer dimers. All genes were normalized to β-actin designed as 
follow: 5’: ccaaccgcgagaagatga 3’: ccagaggcgtacagggatag. Expression levels of the indicated genes 
were calculated by the ΔΔCt method using the dedicated StepOne software. 
11. Liquid Chromatography-Mass Spectroscopy (LC-MS) 
Intracellular metabolites analysis: a predefined number of cells was incubated for 48 hours and 
then quickly washed with ice cold PBS on an ice bath. Cells were then lysed with a dry 
ice/methanol solution (-80°C) of 50% methanol/30% acetonitrile in water and quickly scraped. 
The extracts were mixed at 4°C for 15 minutes and pelleted in a cooled centrifuge (4°C). After 
that, the supernatant was collected for subsequent LC-MS analysis. The amount of extraction 
solution was calculated according to the number of cells present in the sample dish, extrapolated 
using a “counter dish” cultured in the same conditions of the sample dishes. A concentration of 
1ml per 1x106 cells was used in the extraction solutions. 
Extracellular metabolites analysis: 50 µL of cells growth medium were collected after 24 and 48 
hrs of incubation, added to an acetonitrile-water solution and vortexed for 15 minutes. The 
suspension was then centrifuged for 10 minutes at 16000xg at 4°C and the supernatant was 
submitted to LC-MS analysis. 
LC-MS analysis: Intermediates were separated using a liquid chromatography system. The LC 
system consisted of Finnigan Surveyor Autosampler Plus (ThermoElectron, Hemel Hempstead UK) 
and MS Pump Plus (ThermoElectron, Hemel Hempstead UK).  
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The column was Sequant Zic-Hilic (150mm X 4.6 mm i.d. 5 microns) with a guard column (20 
mm X 2.1 mm i.d. 5 microns) from HiChrom, Reading, UK. Mobile phase A: 0.1% formic acid v/v in 
water. Mobile B: 0.1% formic acid v/v in acetonitrile. The flow rate was at 300 μL/minute and 
gradient was as follow: 0 minutes 80% of B, 12 minutes 50% of B, 26 minutes 50% of B, 28 
minutes 20% of B, 36 minutes 20% of B, 37-46 minutes 80% of B.The autosampler tray 
temperature was set at 3°C. 
The LC system was coupled online to an LTQ Orbitrap mass spectrometer (ThermoElectron, 
Hemel Hempstead UK) equipped with an electrospray ionization source set at 4.5 KV in the 
positive ion and negative ion mode. The capillary was set to 35 V. The heated capillary 
temperature was set to 250 °C. Tube lense was set to 100 V for positive and -95 V for negative ion 
modes. The machine was calibrated and tuned with calibration solution freshly before each run. 
The ion current at every mass to charge ratio (m/z) and elution time was measured by the LC-
FTMS. 
Data acquisition was controlled with Xcalibur 2.0 (ThermoElectron). The mass accuracy was 
maintained below 1 ppm due to use of a lock mass. The raw chromatograms were then aligned 
using the software SIEVE™ (ThermoElectron). The integration of the measured ion current over a 
metabolite’s elution time and m/z interval is directly proportional to its absolute abundance in the 
solution. We manually removed from the SIEVE’s output unspecific and misaligned peaks to 
eliminate the noise.  
12. Data analysis and statistics of metabolomic results 
To identify the most significant differences between groups, univariate statistical analysis was 
used. Filtering procedures, such as fold-change analysis, t-test (for paired and unpaired data) and 
ANOVA were applied, as provided by MetaboAnalyst web-based software [Xia J.et al., (2009); Xia 
J.and Wishart D.S., (2011)]. Significantly different data at the probability level of p<0.05 were used 
for further procedures of multivariate analysis, to obtain identification of relevant biomarkers. 
Tentatively, the entire metabolomic data set was submitted to multivariate analysis by means of 
the procedures provided by MetaboAnalyst [Xia J. et al., (2009); Xia J. and Wishart D.S., (2011)] 
and meta-P server [Kastenmüller G. et al., (2011)]. 
Principal Component Analysis (PCA). PCA is an unsupervised method to detect the directions 
which best explain the variance in a data set, transforming a number of possibly correlated 
variables into a smaller number of uncorrelated variables defined as principal components, which 
are linear combinations of the original variables. The first principal component explains as much 
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of the variability in the data as possible, and each following component accounts for the 
remaining variability. The data are represented in a dimensional space of n variables, which are 
reduced into a few principal components; these are descriptive dimensions indicating the 
maximum variation within the data. After the principal components scores have been obtained, 
they can be graphically plotted to observe any groupings in the data set. PCA computation was 
obtained with MetaboAnalyst based on R prcomp package, using singular value decomposition 
algorithm. The covariance matrix and standardized principal component score were selected. The 
scores of the first two principal components were graphically plotted to observe any groupings in 
the data set. 
Cluster analysis. Cluster analysis is a multivariate procedure of exploratory data analysis for 
detecting natural groupings in data. Data classification consists of placing samples into more or 
less homogeneous groups, in order to reveal any relationship among groups. Ward's method 
(minimizing the sum of squares of any two clusters), provided by MetaboAnalyst, was used. 
Distance indices were determined by Pearson’s method. Hierarchical clustering was performed 
with the hclust function provided by R package stat. Results were presented as dendrograms or 
heat maps. 
12.1 Metabolite identification 
The putative masses responsible for the metabolic differentiation between the groups were used 
to make queries in the METLIN (http:// metlin.scripps.edu/), Mass Bank Database (http://www. 
massbank.jp/en/database.html) and Human Metabolome Database (http://www.hmdb.ca/) 
online databases in order to obtain corresponding chemical structures.Keggs Database 
(http://www.genome.jp/kegg/) was used to identify metabolic pathways of interest. 
13. Statistical analyses 
All data are expressed as mean ± SEM. Standard ANOVA procedures followed by multiple pair-
wise comparison adjusted with Bonferroni corrections were performed for cell viability assays. 
Paired t-tests were used to analyse all the other results. Significance was considered at P < 0.05. 
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RESULTS 
Cisplatin is known as one of the more effective chemotherapeutic agent for a wide variety of solid 
tumour [Vincent, 2001] however, despite a consistent rate of initial responses, the treatment 
often results in resistance leading to therapeutic failure. In this project cisplatin-sensitive (2008) 
and cisplatin-resistant (C13) human ovarian cancer cells, whose CDDP IC50 are shown in Table 1, 
have been characterized in order to define mechanisms of resistance not jet discovered and 
possibly useful pharmacological targets. 
 
 
IC50 CDDP (µM)
1.4 
1.31-1.49
2008
10.36
9.96-10.75
C13
 
The ability of certain cancers to rely heavily on glycolytic metabolism, even in the presence of an 
adequate oxygen supply, has been pioneered by Warburg [Warburg O., 1956]. Recently, besides a 
number of molecular alterations, a metabolic reprogramming involved in the faster growth and 
proliferation of cancer cells have been demonstrated. Herein, in order to investigate the 
hypothesis that after repeated exposure to cisplatin, cancer cells might further reprogram their 
metabolism, wild type sensitive and cisplatin-resistant ovarian carcinoma cells and their derived 
transmitochondrial hybrids were phenotyped for metabolic, morphological and molecular 
aspects. 
Table 1: CDDP IC50 of cisplatin-sensitive (2008) 
and cisplatin-resistant (C13) ovarian cancer cells.  
52 
 
1. Phenotyping Of Ovarian Carcinoma Cells Sensitive (2008) And Resistant (C13) To 
Cisplatin 
1.1 Oxygen Consumption 
To investigate the respiratory chain activity of cancer cells, the different rate of basal oxygen 
consumption was measured in viable cells using a Clark-type oxygen electrode. Figure 1 shows a 
significantly lower oxygen consumption in C13 cells, compared to 2008 cells, indicating a 
reduction of mitochondrial respiration in chemoresistant cancer cells. 
2008 C13
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1.2 Effect of Galactose and Rotenone on Cell growth and ATP production 
To test the mitochondrial functionality of cancer cells and to understand their dependency from 
glycolysis for the energy production, cell viability and ATP level were measured after exposure to 
two different experimental tool causing mitochondrial stress. The first experimental strategy was 
to incubate the cancer cells in a glucose-free/galactose medium. Galactose is very slowly 
metabolized through the glycolytic pathway, therefore glycolysis dependent cells are not able to 
survive for a long time unlike those with an efficient oxidative phosphorylation [Reitzer et al., 
1979]. Fig. 2 shows the time course of 2008 and C13 cell proliferation in DMEM or in DMEM 
glucose-free and added with 5 mM galactose. It is evident that in galactose stressed metabolic 
condition, the cell proliferation is lower than in DMEM. Further the effect is more significantly 
pronounced in the cisplatin-resistant cell line. This data suggests a major glucose-dependence of 
C13 whose oxidative phosporylation is not so efficient to counteract the block of the glycolysis. 
 
Figure 1: Oxygen consumption [fmol oxygen/cell/min] 
in 2008 and C13 cells. ***p < 0.001, C13 vs.2008 cells. 
53 
 
 
 
 
 
 
 
The second experimental strategy was to incubate cells with rotenone, an inhibitor of NADH-CoQ 
oxidoreductase (complex I) in the mitochondrial respiratory chain [Pitkänen S. and Robinson B.H., 
(1996)]. The results clearly demonstrate that CDDP-resistant cells (C13) are less sensitive than 
wild-type chemosensitive cells (2008) to the respiratory chain inhibitor (Fig. 3), suggesting a 
possibly lower activity of mitochondria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of galactose on cell viability of 2008 and C13 cells incubated for 24 and 48 hours in DMEM or in 
glucose free/galactose medium. Data are expressed as % of cell number after 24-48 h compared to the t0. Data are 
the mean ± SEM of 3 different experiments. ** p < 0.01, C13 vs 2008; +p < 0.05, +++p < 0.001, galactose vs control. 
Figure 3: Effect of rotenone (0.1-10 µM) on 2008 and C13 cell viability after 24 and 48 hours of treatment. Data are 
expressed as % of cell number compared to the respective control. Data are the mean ± SEM of 3 different experiments. 
*p < 0.05, C13 vs 2008; +++ p. < 0.001 rotenone vs control. 
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The effect of galactose and rotenone was further investigated on ATP generation after 24 hours of 
incubation. As shown in fig. 4, the total ATP is lower in CDDP resistant-cells incubated in a 
glucose-free/galactose medium as compared to basal condition , while is higher after treatment 
with rotenone.  
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1.3 Mitochondrial Mass and Membrane Potential  
Mitochondrial mass and mitochondrial membrane potential (ΔΨm), which is generated by the 
proton gradient across the inner mitochondrial membrane, were both analysed by flow cytometer 
(Fig. 5) and in live confocal microscopy (Fig. 6), using specific different fluorescent probes. Flow 
cytometer assay shows that mitochondrial mass is significantly lower in C13 than in 2008 cells, as 
probed by MFI of 10-Nonyl bromide Acridine Orange (NAO) (fig. 5a); similarly the ΔΨm is lower in 
C13 cells as probed by potential-dependent rhodamine-123 (Rh123) (fig. 5b).  
5b. Rh-123
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Figure 4: Effect of 5mM galactose and rotenone (0.1-10 µM) on 2008-C13 total ATP production. Data are expressed as 
% of nmol ATP/mg protein, compared to the respective control. Data are the mean ± SEM of 3 different experiments. 
*p < 0.05, C13 vs 2008. 
 
Figure 5: Mitochondrial mass (a) and potential (b) in 2008 and C13 cells, measured by flow cytometry and expressed as 
mean fluorescent intensity [MFI] of NAO (25 nM) and Rh123 (10 µM). Each bar represents the mean ± SEM of 5 
independent experiments. **p < 0.01. C13 vs 2008. 
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These results were confirmed by confocal microscopy (Fig. 6). Live cells were incubated with the 
MitoTracker Green (MTG) to probe mitochondrial mass, and with Tetramethyl-Rhodamine 
Methyl-esther (TMRM), to probe ΔΨm. Cumulative images of sequential focal sections were 
acquired and z-stacks of the whole microscopic field were generated in order to measure the 
volume and intensity of the green and red markers. Representative images show significantly 
lower fluorescence intensity in the C13 than in 2008 cells. Furthermore in C13 cells the 
mitochondrial network appear scattered and less structured than in 2008 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MTG TMRM MERGE
2008
C13
2D
3D
2008
C13
Figure 6: Images of 2008 and C13 cells, acquired with Leica confocal microscope (60X) using MTG (100 nM; λec/em= 
490/516) and TMRM (10 nM; λec/em= 544/590).Images acquired in C. Frezza lab (Hutchison/MRC Research Centre, 
Cambridge). 
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In order to reduce the possible artefacts of fluorescence emission due to changes in mitochondrial 
shape and volume, rather than in ΔΨm, the ratiometric (red/green) was calculated (Table 2). 
Results show that the fluorescence intensity of both MTG and TMRM probes is significantly lower 
in resistant-cells (C13), however the ratio TMRM/MTG values are similar suggesting that the 
reduced mitochondrial potential of C13 is not due to a loss of mitochondrial functionality, but to a 
lower mitochondrial mass. 
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1.4 mtDNA content 
In order to understand the lower mitochondrial mass of C13 cells, mtDNA content was analyzed in 
C. Giordano lab (Istituto di Anatomia Patologica, Università “La Sapienza” di Roma). The results 
revealed significantly lower mtDNA levels in the cisplatin-resistant cell line than in wild type 
cancer cells (Fig. 7). 
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Table 2: Mean Fluorescence intensity (MFI) of MitoTracker Green (MTG)and TetraMethyl-
Rhodamine Methyl-esther (TMRM) and their ratio in 2008 and C13 
Fig. 7: mtDNA content measured by qRT-PCR in 
2008 and C13 cells. ***p < 0.001, C13 vs.2008 cells. . 
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1.5 Mitochondrial DNA Sequences  
To better investigate the previously described mitochondrial differences of 2008 and C13 ovarian 
cancer cells, mitochondrial DNA of both cell lines was totally sequenced by C. Giordano group 
(Istituto di Anatomia Patologica, Università “La Sapienza” di Roma) (Tables 3 a-b).  
Table 3a: mtDNA polymorfism in 2008 cells Table 3b: mtDNA polymorfism in C13 cells 
POLYMORPHISM GENE VARIATION 
66delG MT-DLOOP  
309insC MT-DLOOP  
315insC MT-DLOOP  
379 A>T   
709 G>A MT-RNR1 non cod 
1438 A>G MT-RNR1 non cod 
1888 G>A MT-RNR2 non cod 
4769 A>G MT-ND2 syn 
6734G>A MT-CO1 syn 
8860A>G MT-ATP6 T-A 
15287T>C MT-CYB F-L 
15326A>G MT-CYB T-A 
16519T>C MT-DLOOP  
 
 
POLYMORPHISM GENE VARIATION 
66delG MT-DLOOP  
263A>G MT-DLOOP  
315insC MT-DLOOP  
379 A>T   
709 G>A MT-RNR1 non cod 
1438 A>G MT-RNR1 non cod 
1888 G>A MT-RNR2 non cod 
4769 A>G MT-ND2 syn 
6734G>A MT-CO1 syn 
8156 heteroplasmy 
G>T * 
MT-CO2 V-L 
LD=0,53 
8860A>G MT-ATP6 T-A 
12018 heteroplasmy 
C>T ** 
MT-ND4 T-I 
LD=0,69 
13828 heteroplasmy 
C>T ** 
MT-ND5 L-P 
LD=0,05 
14470T>A MT-ND6 syn 
15287T>C MT-CYB F-L 
15326A>G MT-CYB T-A 
16519T>C MT-DLOOP  
 
The comparison between 2008 and C13 cells was analyzed by an electropherogram and three 
levels of heteroplasmy were identified in C13 cells: 8156 G>T, 12018 C>T, 13828 C>T. These 
polymorphisms were further analyzed by the PolyPhen program on the site: 
http://genetics.bwh.harvard.edu/pph2/, and the polymorphisms 8156 G>T and 13828 C>T 
resulted with low probability to be pathogenic, while the polymorphism 12018 C>T was 
borderline, suggesting further genetic study. 
 
 
* 30% of mtDNA polymorfism rate in C13 
compared to 2008 cells ; 
** 50% of mtDNA polymorfism rate in C13 
compared to 2008 cells. 
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1.6 1H-NMR  
Nuclear Magnetic Resonance (NMR) spectroscopy is a non-invasive, accurate technique 
increasingly applied to define the metabolic phenotype of tissues or cells. Even if NMR detects 
only a fairly small number of metabolites, it can be used to monitor different metabolic pathways 
and to delineate the fingerprint of different cell lines. 1H-NMR analysis were performed in Mammi 
lab by M. Bellanda (Dipartimento di Scienze Chimiche, Università degli Studi di Padova). Fig. 8a 
shows representative 1H-NMR spectra of 2008 and C13 cell samples, and a typical deconvolution 
pattern is reported in Fig. 8b. Two-dimensional and one-dimensional proton spectra were used 
for signal identification and signal quantification, respectively, as described in the Methods 
section. For normalization purposes, the peak area were divided by the area of the peak at 0.96 
ppm, deriving from polypeptide chains and, because indicative of cell mass, used as an internal 
reference for one-dimensional spectra [Luciani et al., 2009].  
 
 
 
 
 
 
 
 
 
 
The 1H-NMR spectra of 2008 and C13 cell lines showed similar general features, however, at a 
more detailed analysis some significant differences were observed as reported in Tables 4-5. The 
levels of glutathione detected was about 1.6 times higher in C13 cells in comparison to sensitive 
2008 cells (Table 4). Furthermore, most of mobile lipid (ML) signals, that were intense for both 
cell lines, in agreement with data reported for many cancer cells, were significantly higher in C13 
than in 2008 cells: at 0.90 ppm [CH3-], 1.29 ppm [-(CH2)n-], at 1.32 ppm [-CH2- CH2-CH=], at 1.59 
ppm [-CH2-CH2-CO-] and at 2.24 ppm [-CH2- CO] (Table 5).  
A B
Figure 8: (A) Representative 1H NMR spectra of 2008 [bottom] and C13 cells [top]. The regions between 
0.6 and 1.8 ppm of the two spectra (highlighted in gray) are expanded and superimposed in the inset. 
The spectra were normalized with respect of the polypeptide CH3 signal at 0.94 ppm (M). Signals of 
mobile lipids at 0.90 ppm [CH3-], 1.29 ppm [-(CH2)n-], and 1.59 ppm [-CH2-CH2-CO-] are indicated. (B) 
Example of the deconvolution pattern of the region 0.6-1.8 ppm in the spectrum of C13 cells. 
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Table 4: Peak Area Ratios of the Glutathione signals to the Polypeptide –CH3 resonance at 0.94 
ppm, in 2008 and C13 cells.  
 
 
 
Data are the Mean ± SD of 7 and 5 measurements. *p<0.05, ***p<0.001, Student’s t test, comparison 2008 vs. C13 cells. 
Table 5: Peak Area Ratios of Mobile Lipid Signals to the Polypeptide –CH3 resonance at 0.94 
ppm, in 2008 and C13 cells.  
 
 
 
 
 
Data are the Mean ± SD of 7 and 5 measurements. *p<0.01, **p<0.005, ***p<0.001, Student’s t test, comparison 2008 
vs. C13 cells.  
 
To better appreciate differences between wild-type and CDDP-resistant cells, a multivariate 
analysis by means of principal component analysis (PCA) was conducted for glutathione and MLs 
and peak areas detected by 1H-NMR spectra. As shown by the plot in Fig. 9, the PC1 vs PC2 scores 
indicate that 2008 and C13 are clearly separated cell population. 
 
 
 
 
 
 
 
Figure 9: Scores plot of the 
Principal Component Analysis 
(PC1 vs PC2) conducted on MLs 
and GSH peak area in 
1
H-NMR 
spectra of 2008   and C13   cells 
(see Tables 2 and 3; data are the 
mean ± SEM of 5-7 
measurements). The two cell lines 
present well-distinct groupings, 
suggesting an overall different 
metabolic pattern. The ellipses 
indicate the 68% confidence 
interval for each group. 
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1.7 Nile Red Neutral Lipid Staining  
It has been demonstrated that in many tumours, cells catabolize glucose at a rate that exceeds 
bio-energetic needs by shifting from oxidative to glycolytic metabolism [Shaw R. J., 2006; Bui T. 
and Thompson C.B., 2006; Garber K., 2006]. Furthermore, frequently de novo fatty acids synthesis 
is increased [Kuhajda F.P., 2000]. 
To confirm the mobile lipids (MLs) results, the intracellular lipid content of 2008 and C13 cells was 
stained with Nile red neutral lipid dye and the fluorescence was observed by confocal microscopy 
(Fig. 10A). Results show neutral lipid accumulation mainly into cytoplasmic droplets in both cell 
lines, but more intensely labelled spots in resistant cells (C13) than in cisplatin sensitive cells 
(2008). Quantitative determination of Nile red fluorescence was therefore carried out with 
cytofluorimetry (Fig. 10B), demonstrating about two fold more elevated MFI in C13 cells than in 
2008 cells. 
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Figure 10: Nile red neutral lipid staining in 2008 and C13 cells. (A) Images acquired with a Nikon C1 confocal microscope 
and Nikon EZ-C1 software (version 2.10), magnification 60X. (B) Mean fluorescence intensity [MFI] measured by flow 
cytometry. All images are exemplificative of at least four different experiments. 
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2. Phenotyping of Transmitochondrial Hybrids derived from 2008 and C13 Cells  
To deeply investigate a possible role of the mitochondria on the metabolic remodelling observed 
in cisplatin-resistant ovarian cancer cells, the hybrid cell model was used. Transmitochondrial 
hybrids (H2008 and HC13) were generated by fusion of ovarian carcinoma cells (2008-C13), 
previously enucleated, with mtDNA depleted osteosarcoma cells (206-ρ°). This cellular model 
permits to study the influence of mtDNAs on cell function, independently from its own nuclear 
DNA. Firstly the hybrids generated from ovarian carcinoma cells (H2008 and HC13) were 
sequenced for their mitochondrial DNA, to confirm their genetic stability. Results showed the 
same polymorphisms observed in the parental cells (data not shown). Therefore, hybrids were 
phenotyped for comparison with parent cell lines.  
2.1. Cell viability and apoptosis following CDDP treatment  
The effect cisplatin (0.1-100 µM). was evaluated on cytoplasmatic hybrids (H2008 and HC13) after 
24 hours of exposure. The experiments, performed by MTT test (Fig. 11a) and trypan blue 
exclusion assay (Fig. 11b), show a concentration-dependent activity in both cell lines, whose drug 
sensitivity is practically superimposable. 
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As shown by flow cytometer assay (Fig. 12), also the percentage of apoptotic cells after cisplatin 
treatment (1-10 μM) is similar between H2008 and HC13, demonstrating that the two cybrid cell 
lines, having the same nuclear background, lose the different susceptibility to cisplatin observed 
in 2008 and C13.  
Figure 11: Effect of cisplatin (0.1-100 µM) on cybrids’ cell viability measured by MTT (a) and trypan blu exclusion 
assay (b). Data are the mean ± SEM of 4 different experiments in quadruplicate for MTT and in duplicate fo Trypan 
blu assay. ***p < 0.001, **p < 0.01; CDDP vs control. 
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2.2 Oxygen consumption  
To investigate the role of nuclear genome on the respiratory chain's activity, the oxygen 
consumption was parallely detected in ovarian cancer cells and in their derived cybrids. The result 
(Fig. 13) is expressed as ratio C13/2008 compared with HC13/H2008 and highlights that, 
differently to ovarian cancer cells, the hybrids cell lines haven’t significant differences in the 
oxygen consumption. 
Figure 12: Apoptosis induced by cisplatin (1-10 µM) in H2008 and HC13. In Fig. 12(A) 
there are plots obtained by flow cytometer. In Fig 12(B) data are expressed as 
percentage of apoptotic cells under basal condition (control) and after 24h of 
treatment with CDDP. ***p < 0.001, **p < 0.01, *p < 0.05; CDDP vs control. 
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2.3. Effect of galactose and rotenone on Cell Growth 
As depicted in Figures 14 a-b, HC13 and H2008 didn’t show any difference in cell growth when 
incubated in glucose free/galactose medium or in the presence of (0.1-10 μM) rotenone. These 
results evidence a similar sensitivity to mitochondrial stress. 
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Figure 13: Oxygen consumption [fmol 
oxygen/cell/min] in ovarian cancer cells (C13/2008) 
and their derived cybrids (HC13/H2008). ***p < 0.001, 
cybrids vs tumoral cells. 
14a 
Figure 14a: Effect of 5mM galactose on H2008 and HC13 cell viability after 24 and 48 hours of treatment. Data are 
expressed as as % of cell number after 24-48 h compared to the t0. Data are the mean ± SEM of 3 different experiment. 
***p < 0.001, **p < 0.01; galactose vs control. 
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2.4 Mitochondrial Mass and Membrane Potential  
Markers of mitochondrial functionality were assayed in H2008 and HC13 hybrids and the results, 
expressed as ratio (C13/2008) and (HC13/H2008), were compared with those in 2008 and C13 
parent cells.  
As previously observed, results confirm that C13 CDDP-resistant cells, as compared to wild type 
2008 cells, present a fall of mitochondrial potential (Fig 15b), associated with a significantly 
reduced mitochondrial mass (Fig. 15a). By contrast no significant differences exist between HC13 
and H2008 hybrids, confirming that there is a nuclear control in the mitochondrial remodelling 
undergone from the cisplatin-resistant cells.  
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Figure 15: Mitochondrial mass (a) and potential (b) in ovarian cancer cells and in their derived cybrids, measured by 
flow cytometry and expressed as mean fluorescent intensity [MFI] of NAO (25 nM) and Rh123 (10 µM). Each bar 
represents the mean ± SEM of 5 independent experiments. **p < 0.01. cybrids vs cancer cells. 
Figure 14b: Effect of rotenone (0.1-10 µM) on H2008 and HC13 cell viability after 24 and 48 hours of treatment. Data 
are expressed as % of cell number compared to the respective control. Data are the mean ± SDM of 3 different 
experiment. ***p < 0.001; rotenon vs control. 
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The cytofluorimetric data of mitochondrial membrane potential and mitochondrial mass were 
consolidated with in live microscopy whose images are shown in fig. 16 and the ratiometric 
quantification of red signal on green one (TMRM/MTG) of hybrids is reported in Table 6. 
HC13
H2008
MTG TMRM MERGE
HC13
H2008
2D
3D
 
 
 
 
108,69    20,24
105,19    32,21
1,56
1.23-1.89
72,48 14,01HC13
1,49
1.09-1.79
70,92 20,29H2008
TMRM/MTGTMRMMTGMFI
Cell lines
+-
+-
+-
+-
 
Table 6: Mean Fluorescence intensity (MFI) of MitoTracker Green (MTG) and TetraMethyl-
Rhodamine Methyl-esther (TMRM) and their ratio in H2008 and HC13 
Figure 16: Images of cybrids cells acquired with Leica confocal microscope (60X) using MTG (100 nM; λec/em= 490/516) 
and TMRM (10 nM; λec/em= 544/590). Images acquired in C. Frezza lab (Hutchison/MRC Research Centre, Cambridge). 
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2.5 mtDNA content 
The last mitochondrial parameter that was investigated, is the mtDNA content. Results confirm 
that the levels of mtDNA are significantly lower in the resistant cell line as compared with the 
sensitive, while no significant differences were observed in cybrid cell lines (Fig. 17). 
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Fig. 17: mtDNA content measured by qRT-PCR in ovarian 
cancer cells (2008-C13) and their derived cybrids (H2008-
HC13). ***p < 0.001, cybrids vs.tumoral cells. . 
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3. Metabolic reprogramming  
3.1 Nuclear transcription factors and target genes 
HIF-1 is an heterodimeric complex, consisting of a constitutive subunit HIF-1β and an hypoxia 
inducible subunit HIF-1α: under normoxia, HIF-1α is rapidly degraded, while during hypoxia is 
stabilized and translocates into the nucleus, where it dimerizes with HIF-1β, forming the 
transcriptionally active complex inducing several target genes to favour the metabolic adaptation 
[Papandreou I. et al., (2006); Wang et al., (1995); Pugh C.W. and Ratcliffe P.J., (2003)].  
In this study basal HIF-1α expression was determined in ovarian cancer cells and in their cybrids 
under basal condition. Interestingly, HIF-1α was measurable in all cell lines, even if mostly in C13 
cells (Figure 18).  
HIF1-α 120 KDa
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Intriguingly c-Myc is a nuclear transcription factor capable to induce genes involved in glycolysis, 
but in contrast to HIF-1, promoting mitochondrial biogenesis under non hypoxic conditions [Kim J. 
W. et al., (2004); Li F. Y. et al., (2005); Zhang H. et al. (2007)]. In this study the crosstalk between 
HIF-1 and cMYC transcription factors was investigated in ovarian cancer cells and in cybrid cell 
lines, by measuring the mRNA levels of c-Myc and of several genes involved in the regulation of 
the glycolytic flux (Fig 19). In particular some genes controlled both by HIF-1α and c-MYC (GLUT1-
LDHA-PFKM-PGK1), and BNIP3, gene induced only by HIF-1α, were analysed in C. Frezza lab 
(Hutchison/MRC Research Centre, Cambridge).  
 
 
Fig 18: HIF-1α expression in normoxia. Optical density (O.D.) was normalized to 
that of actin. Data are the mean±SEM of four determinations. *p < 0.05 C13 vs 
2008 and hybrid lines. 
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As expected significant differences were observed between 2008 and C13 wild type cells, being 
GLUT1 and BNIP3 mRNA level more elevated and LDHA-PFKM-PGK1 lower in cisplatin-resistant 
than sensitive cells. Interestingly also c-MYC was down-regulated in cisplatin-resistant cells. By 
contrast only marginal differences were observed between the two hybrid cell lines, having 
similar nuclear background. 
3.2 LC-MS  
To further investigate the difference between metabolic signature of sensitive and resistant 
ovarian cancer cells, an unsupervised endo-metabolomic analysis was performed in C. Frezza lab 
(Hutchison/MRC Research Centre, Cambridge), using LC-MS. The total ion current of the different 
samples was used as a confirmation for normalized input. The early unsupervised multivariate 
analysis conducted by E. Ragazzi (Dipartimento di Scienze del Farmaco, Università degli Studi di 
Padova) for all peak intensities detected from spectra of cell extracts, is shown in Figures 20 a-b. 
Fig 19: mRNA content of c-Myc and of target genes (of HIF-1α and c-Myc) 
under normoxia. mRNA measured by qRT-PCR and normalized with the 
actin levels. Data are expressed as ratio of C13/2008 mRNA content. 
Mean±SEM of four determinations. ***p < 0.001, **p < 0.01, *p < 0.05, 
C13 vs.2008; HC13 vs H2008. 
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Both hierarchical clustering and the principal component analysis show a clear separation of 2008 
and C13 cells, confirming 1H-NMR results obtained in live cells analysis.  
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A detailed identification of the most relevant peaks and the relative signal quantitative intensity 
analysis, revealed significant differences in the metabolic profile of cisplatin-sensitive and 
resistant-cells, reported as the ratio C13/2008 in Figure 21.  
 
 
 
 
 
 
 
The results show a significant lower aminoacid content in the cisplatin-resistant cells compared to 
the sensitive cell line. By contrast there are higher levels of antioxidant glutathione and taurine, as 
well as of several membrane phospholipids (phosphacholines, phosphaethanolamines, 
sphingomyelines) in C13 cells than in 2008 ones.  
Fig 20: Unsupervised multivariate analysis of LC-MS of ovarian cancer cisplatin intracellular extracts: a) hierarchical 
clustering and b) principal component analysis (PCA) of peak signals. 
Fig 21: C13 / 2008 ratio of peak intensity signals of selected metabolites revealed by LC-MS analysis.  
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The intensity of peak signals for each metabolite, measured by LC-MS in 2008 and C13 cells as 
well the mean variation of the amount between the two lines, calculated from 3 different spectra 
in duplicate is reported in Figs. 22 a-d.  
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Fig 22a. Aminoacid content in 2008 and C13 cells. Box plots of data indicate median (horizontal live), 25th 
and 75th percentile (box margins), maximum value (wiskers’s end). 
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Fig 22b. Phospholipid content in ovarian cancer cells. 
Fig. 22c. GSH and taurine levels in ovarian cancer cells. 
Fig. 22d. Pyridoxine (Vit. B6) and 2-methylpiridine in ovarian cancer cells. 
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These results suggest that C13 cells might increase their intracellular defence system as well as 
the aminoacidic consumption for macromolecules synthesis, thus counteracting the cytotoxicity 
of cisplatin. 
3.3. Effect of glutamine deprivation on cell viability 
Glutamine, whose carbons can enter into the tricarboxylic acid (TCA) cycle, has been revised as an 
essential bioenergetic and anabolic substrate for many cancer cell types. Since LC-MS showed a 
lower glutamine level in cisplatin-resistant C13 cells than in 2008 sensitive cells, cell proliferation 
of the two cell lines were studied in medium with or without glutamine (Fig. 23). 
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Results clearly showed that the C13 cell growth is significantly reduced when coltured in 
deprivation of glutamine, while no statistical differences were detected for 2008 cells. Data 
suggest that C13 cells have a major dependence from glutamine aminoacidic substrate as well as 
from glucose, as previously shown (see fig. 2 of cell viability in galactose). 
 
 
 
 
 
 
 
Fig 23: Effect of glutamine deprivation on 2008 and C13 cell viability (24 and 48 hours of treatment). Cell viability was 
measured by the blue dye exclusion assay. Data are expressed as percentage of the cell number compared to the t0. 
Data are the mean ± SEM of 3 different experiments. ***p < 0.001, *p < 0.05 treatment vs control. 
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DISCUSSION 
In this study the shift of cisplatin-resistant ovarian cancer cells from OXPHOS to a glycolytic 
metabolism with characteristics of a lipogenic phenotype is shown. By using trans-mitochondrial 
cell model, it was possible to study the mitochondrial DNA and verify the nucleus involvement in 
the mitochondrial and metabolic remodelling observed in cisplatin-resistant cells. Cisplatin is one 
of the most potent chemotherapeutic agents used in the treatment of several types of tumours, 
including ovarian carcinoma [Galansky M., (2006)]. Even if the benefits of cisplatin are largely 
recognized, the therapeutic effectiveness of the drug is limited by the onset of cisplatin resistance 
[Koberle B. et al., (2010)], whose mechanisms are still not clearly understood. Indeed the 
resistance to cisplatin is a multifactorial phenomenon including, among others, changes in drug 
transport and accumulation, increased DNA repair and detoxification systems, and evasion from 
apoptotic cell death [Rabik C.A. and Dolan M.E., (2007); Boulikas T. et al., (2007)]. Recent studies 
have shown that also the density of mitochondria might affect the chemoresistance suggesting 
that mitochondria are a potential target for cisplatin. In this study, these issues have been 
investigated by different experimental approaches. Results from early research in our laboratory 
demonstrated that in cisplatin-resistant cells (C13) the respiratory chain activity is lower and the 
dependency on glucose is higher than in cisplatin-sensitive cells 2008 [Montopoli M. et al., 
(2011)]. It was also observed that cisplatin is equipotent in both mtDNA-deprived 2008-ρ0 and 
C13-ρ0 cells, demonstrating that mtDNA lack decreases drug sensitivity. In the present study, 
oxygen consumption, ATP generation, cell viability in metabolic stress condition, mitochondrial 
potential/mass and mtDNA content were measured in 2008 and C13 cells; the results showed a 
significant reduction of all mitochondrial parameters in cisplatin resistant cells. Since 
mitochondrial DNA mutations and mitochondrial deficits have been reported for a wide variety of 
cancers [Wallace D.C., (2011)], mitochondrial DNA of 2008 and C13 cells was completely 
sequenced. Results showed the same polymorfisms between the two cell lines; however, only in 
C13 cells heteroplasmic mutations were identified: two classified at low probability of 
pathogenicity (m.13828 C> T, m.8156 G> T) and one borderline to be pathogenic (m.12018 C> T).  
In order to investigate if mtDNA might be responsible of the altered mitochondrial function of C13 
cells, we have taken advantage of an innovative experimental model such as the trans-
mitochondrial hybrids (cybrids). Cybrids are cytoplasmatic hybrid cells derived from the fusion of 
enucleated cells (cytoplasts or mitochondria donor) with mtDNA-depleted cells (ρ0 or nucleus 
donor). This procedure was chosen to study the influence of mtDNA independently from the 
original nDNA, because in an identical nuclear background. This experimental model has been 
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recently used in in vitro studies of different mitochondrial diseases [Giordano C. et al., (2012); 
Perli E. et al., (2012)].  
In this study cybrids (H2008 and HC13 cells) were generated from 2008 and C13 cells and 
phenotyped. mtDNA sequences were identical to those in parent cells. However the two hybrid 
clones showed similar sensitivity to cisplatin cytotoxicity as well as similar mitochondrial 
parameters that are amenable to those of 2008. These results indicated that the heteroplasmic 
mtDNA mutations themselves were not causative factors of the reduced mitochondrial activity of 
C13 resistant cells that is thus probably associated to nuclear factors. It is indeed known that the 
coordination between nuclear and mitochondrial genomes is required in all cellular types. In the 
last years, increasing evidences have suggested that growth signalling pathways directly control 
cell metabolism, growth and proliferation through the regulation of metabolic enzymes [Cairns 
R.A. et al. (2011), Ward P.S. et Thompson C.B. (2012)]. It is known that many cancer cells are 
characterized by alteration of several oncogenes and tumour suppressor genes that can lead to 
changes of important energy metabolism pathways such as glucose transport, tricarboxylic acid 
(TCA) cycle, glutaminolysis, oxidative phosphorylation of the mitochondrial respiratory chain and 
pentose phosphate pathway (PPP) [Chen J.Q. and Russo J., (2012)]. The hypoxia-inducible factors 
(HIFs) and c-MYC are critical factors for tumorigenesis in a large number of human cancers. Acting 
alone, HIF and c-Myc partially regulate the adaptation mechanisms that cancer cells undergo in a 
low O2 microenvironment. However, acting in concert, these transcription factors reprogram 
metabolism, protein synthesis, and cell cycle progression to support bioenergetics and cell 
survival [Gordan J.D. et al., (2007)]. It is also known that HIF and c-Myc can directly act on 
mitochondria with opposite effects: whereas c-Myc may positively regulate mitochondrial mass 
promoting mitochondrial biogenesis [Kim J. W. et al., (2004); Li F. Y. et al., (2005); Zhang H. et al. 
(2007)], HIF is able to reduce mitochondrial mass, inducing mitophagy or inhibiting c-Myc [Zhang 
H. et al., 2007]. These data prompted us to explore these important transcription factors and 
some of their target genes involved in glycolytic flux and mitophagic processes. Results showed no 
differences between hybrid cell lines, while cisplatin-resistant cells (C13), as compared to 2008 
cells, present higher levels of HIF and BNIP3, the latter being a gene (protein-coding) triggering 
mitochondrial-selective autophagy. [Zhang et al. 2008; Bellot et al. 2009]. By contrast, qRT-PCR 
showed lower levels of c-Myc well correlated with the reduced mitochondrial potential/mass and 
the lower mtDNA content measured in C13 cells. Molecular findings also showed differences in 
GLUT1, LDHA, PFKM and PGK1 levels and, in order to better understand the C13 profile, 
metabolomic studies were undertaken.  
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Although metabolic reprogramming is thought to be essential for rapid cancer cell proliferation, a 
systematic characterization of the metabolic pathways in transformed cells is lacking, and the 
contribution of these pathways remains unclear [Hsu P.P. and Sabatini D.M., (2008)]. Studies of 
cancer metabolism have examined relatively few cell lines, and have largely focused on the 
intracellular metabolite pools [Sreekumar A. et al., (2009)], or have relied on isotope tracing to 
estimate metabolic flux through a limited number of reactions [DeBerardinis R.J. et al., (2007)]. 
1H-NMR spectroscopy and liquid chromatography combined with orbitrap-based mass 
spectroscopy (LC-MS) have recently emerged as invaluable analytical tools, crucial to uncover the 
determinants of the metabolic transformation of cancer cells but also to discover potential 
tumour targets. Data obtained by 1H-NMR spectra (in vivo cell samples) and LC-MS spectra (cell 
extracts), showed different fingerprints highlighted from hierarchical clustering methods. In 
particular C13 cells, compared to 2008 cells, present a significant increase of glutathione, taurine, 
mobile lipids and phospholipids (phosphacholines, phosphoethanolamine, sphingomyelin), 
pyridoxine, 2-methylpyridine, but a lower aminoacid content.  
Glutathione was expected to be higher in C13 than in 2008 cells since it is one of the well known 
mechanisms of resistance to cisplatin, whereas the unexpected increase of taurine as molecule 
with antioxidant activity was an interesting result to better investigate.  
Most of the carbon for fatty acid synthesis is derived from glucose, but also glutamine uptake 
appears to be critical for lipid synthesis in that it supplies carbon in the form of mitochondrial 
oxaloacetate to maintain citrate production in the first step of the TCA cycle [Wise D.R. et al., 
(2011); Metallo C.M. et al., (2012); Mullen A.R. et al. (2012)]. In this regard glutamine has been re-
discovered as an essential bioenergetic and anabolic substrate for many cancer cell types. In C13 
cells the level of TCA intermediates were not different from 2008 cells, therefore it might be 
assumed that in C13 cells, compared with 2008, there is a higher consumption of glutamine as 
well as the other aminoacids for a faster substrates synthesis and cell duplication, as confirmed by 
the low C13 proliferation in glutamine-free medium. 
The fundamental role of phospholipid in cellular structure is well known. Recent work shows that 
intact PLs act as signaling molecules by modulating the activity of nuclear hormone transcription 
factors responsible for tuning genes involved in metabolism, lipid flux, steroid synthesis and 
inflammation [Musille P.M. and Kohn J.A.; (2013)]. The reorientation of signaling pathways leads 
to the expression and/or activation of various enzymes which participate in aerobic glycolysis 
allowing cancer cells to produce energy (ATP) but also the nucleotides, aminoacids, and lipids 
required for proliferation. Cancer cells are highly dependent on de novo lipid synthesis. In this 
scenario, resistant ovarian tumour cells (C13) might redirect glycolytic intermediates toward de 
novo fatty acid synthesis, to maintain a constant supply of lipids to fuel membrane production in a 
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highly-proliferating cell population. Furthermore, 1H-NMR and Nile red staining, showed us that 
the altered lipid metabolism of C13 cells, culminates in the accumulation of newly formed lipids in 
cytoplasmic lipid droplets. 
Overall, all the results of this study depict a scenario in which C13 resistant cells can be defined as 
pseudohypoxic phenotype, since they have reformulated their energetic metabolism, presumably 
bypassing mitochondria that are an important target of cisplatin. Following this hypothesis, HIF-
1α overexpression might be crucial to direct substrates toward glutaminolysis and lipid synthesis. 
In conclusion, cisplatin-resistant ovarian cancer cells adopt a metabolism designed to favor their 
development and to adapt themselves to the microenvironment. A 'lipogenic categorization' of 
cisplatin-resistant ovarian cancer cells may also innovate the molecular rationale to identify and 
develop a new generation of therapeutic agents, interfering with both the initiation of primary 
carcinomas and the invasive progression of cancer cells. Although further understanding of the 
the metabolomic fingerprints of cisplatin-resistant cells remains to be elucidated, anti-metabolic 
strategies associated with the current platinum chemotherapie, could sap the mechanisms of 
cisplatin chemoresistance and improve their efficacy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
REFERENCES 
Andersen M.R., Goff B.A., Lowe K.A., Scholler N., Bergan L., Dresher C.W., Paley P. and Urban N.; (2008). 
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer: 113(3):484-9. 
Andrews P.A., Murphy M.P., Howell S.B.; (1988). cis-Diamminedichloroplatinum(II) accumulation in 
sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48(1):68–73.  
Arner ES.J., Nakamura H., Sasada T., Yodoi J., HOmgren A., Spyrou G.; (2001). Analysis of the inhibition of 
mammalian thioredoxin, thioredoxin reductase; glutaredoxin by cis-diamminidischloroplatinum (II) and its 
major metabolite, the glutathione-platinum complex. Free Radic. Biol. Med. 2001;31:1170–1178.  
Arnesano F. and Natile G.; (2008). “Platinum on the road”: interactions of antitumoral cisplatin with 
proteins. Pure and Applied Chemistry: 80(12):2715–2725. 
Aylon Y., Oren M.; (2007). Living with p53, dying of p53. Cell: 130(4):597-600. 
Baracca A., Chiaradonna F., Sgarbi G., et al.; (2010). Mitochondrial Complex I decrease is responsible for 
bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta: 1797(2):314-323. 
Bauer D.E. et al.; (2005). ATP citrate lyase is an important component of cell growth and transformation. 
Oncogene: 24:6314-6322. 
Bensaad K., Tsuruta A., Selak M.A., et al.; (2006). TIGAR, a p53 inducible regulator of glycolysis and 
apoptosis. Cell: 126(1):107-120. 
Berardi M.J., Fantin V.R.; (2011). Survival of the fittest: metabolic adaptations in cancer. Curr Opin Genet 
Dev. 21 (1): 59-66.;  
Berg J.M., Tymoczko J.L., Stryer L.; (2002). Biochemistry. W.H. Freeman and Company, New York. 
Bidoli E., La Vecchia C., Montella Dal Maso L., Conti E., Negri E., Scarabeli C., Carbone A., Decarli A., 
Franceschi S.; (2002). Nutrient intake and ovarian cancer: an Italian case-control study. Cancer Cause and 
Control; 13: 255-261. 
Bignami M., Casorelli I., Karran P.; (2003). Mismatch repair and response to DNA-damaging antitumour 
therapies. EurJ Cancer: 39:2142-9. 
Binks S.P. and Dobrota M.; (1990). Kinetics and mechanism of uptake of platinum-based pharmaceuticals 
by the rat small intestine. Biochem. Pharmacol. 40, 1329. 
Bos J.L.; (2005). ras oncogenes in human cancer: a review [J]. Cancer Res, 1989,49(17):4682-4689. 
Bosl G.J. and Motzer R.J., (1997). Testicular germ-cell cancer. N Engl JMed. 337:242-54. 
Bookman M.; (2005). Standard treatment in advanced ovarian cancer in 2005: the state of the art. 
International Journal of Gynecological Cancer: 15:212–220. 
Boulikas T. and Vougiouka M.; (2003). Cisplatin and platinum drugs at the molecular level. (Review). Oncol 
Rep. 10(6):1663-82. 
Brunelle J.K., Bell E.L., Quesada N.M., et al.; (2005) Oxygen sensing requires mitochondrial ROS but not 
oxidative phosphorylation. Cell Metab. 1(6):409-414. 
Bui T. and Thompson C.B.; 2006. Cancer’s sweet tooth. Cancer Cell: 9, 419-420. 
Buller R.E.; (2003). Mismatch repair gene expression defects contribute to microsatellite instability in 
ovarian carcinoma. Cancer: 98: 2199-206. 
78 
 
Byun S.S., Kim S.W., Choi H., Lee C., Lee E.; (2005). Augmentation of cisplatin sensitivity in cisplatin-
resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related 
enzyme activities. BJU Int. 95(7):1086–90.  
Carling D., Sanders M.J., Woods A.; (2008). The regulation of AMP-activated protein kinase by upstream 
kinases. Int J Obes: 32:55-59.  
Cepeda V., Fuertes M.A., Castilla J., Alonso C., Quevedo C., Pérez J.M.; (2007). Biochemical mechanisms of 
cisplatin cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry: 7(1):3–18. 
Chaney S.G. and Sancar A. J.; (1996). Proceedings: Actions of some drugs on enzymes involved in DNA 
repair and semi-conservative DNA synthesis. Natl Cancer Inst. 88, 1346. 
Chapuis N., Tamburini J., Green A.S., et al.; (2010). Perspectives on inhibiting mTOR as a future treatment 
strategy for hematological malignancies. Leukemia: 24 (10):1686 -1699. 
Chesney J., Mitchell R., Benigni F., et al.; (1999). An inducible geneproduct for 6-phosphofructo-2- kinase 
with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci 
U S A: 96(6):3047-3052. 
Chiaradonna F., Gaglio D., Vanoni M., et al.; (2006). Expression of transforming K-Ras oncogene affects 
mitochondrial function and morphology in mouse fibroblasts. Biochim BiophysActa: 1757(9-10):1338-1356. 
Cho K.R. and Shi I.M.; (2009). Ovarian Cancer. Annual Rev Pathol. 4:287-313. 
Chun S.Y., Johnson C., Washburn J.G., et al.; (2010). Oncogenic KRAS modulates mitochondrial metabolism 
in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer: 9:293. 
Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., Viñolas N., Paz-Ares L., Lopez-
Vivanco G., Muñoz M.A., Felip E., Alberola V., Camps C., Domine M., Sanchez J.J., Sanchez-Ronco M., 
Danenberg K., Taron M., Gandara D., Rosell R.; (2007). Customizing cisplatin based on quantitative excision 
repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 
25: 2747-54.)  
Crino P.B., Nathanson K.L., Henske E.P.; (2006). The tuberous sclerosis complex. N Engl J Med. 
355(13):1345-1356. 
Cullen K. J., Yang Z., Schumaker L. and Guo Z.; (2007) Mitochondria as a critical target of the therapeutic 
agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 39, 43–50 
Dang C.V., Le A., Gao P.; (2009). MYC induced cancer cell energy metabolism and therapeutic 
opportunities. Clin Cancer Res15(21):6479-6483. 
Dan H.C., Sun M., Kaneko S., et al.; (2004). Akt phosphorylation and stabilization of X-linked inhibitor of 
apoptosis protein (XIAP) The Journal of Biological Chemistry: 279(7):5405–5412.  
Datta S.R., Brunet A., Greenberg M.E.; (1999). Cellular survival: a play in three akts. Genes and 
Development: 13(22):2905–2927.  
DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B.; (2007). Beyond 
aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for 
protein and nucleotide synthesis. Proc Natl Acad Sci U S A: 104(49):19345-50. 
DeBerardinis R.J., Lum J.J., Hatzivassiliou G., et al.; (2008). The biology of cancer: metabolic 
reprogramming fuels cell growth and proliferation. Cell Metab. 7(1):11-20. 
DePriest P.D., Banks E.R., Powell D.E., et al.; (1992). Endometrioid carcinoma of the ovary and 
endometriosis: the association in postmenopausal women. Gynecol Oncol. 47(1): 71-5. 
79 
 
Desouki M.M., Kulawiec M., Bansal S., Das G.M., Singh K.K.; (2005). Cross talk between mitochondria and 
superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol Ther. 4:1367-73. 
Devarajan P., Savoca M., Castaneda M.P., Park M.S., Esteban-Cruciani N., Kalinec G., Kalinec F.; (2002). 
Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res. 
174:45.  
Dornish JM, Pettersen EO.; (1985). Protection from cis-dichlorodiammineplatinum-induced cell inactivation 
by aldehydes involves cell membrane amino groups. Cancer Lett. 29(3):235–43.  
Dornish JM, Melvik JE, Pettersen EO.; (1986). Reduced cellular uptake of cis-dichlorodiammine-platinum by 
benzaldehyde. Anticancer Res. 6(4):583–8.] 
Dornish JM, Pettersen EO.; (1989). Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by 
benzaldehyde derivatives. Cancer Lett. 46(1):63–8.  
Dunn J.E. Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California 
and Japan. Cancer Res. 35(11 Pt. 2): 3240-5. 
Duvel K., Yecies J.L., Menon S., et al.; (2010). Activation of a metabolic gene regulatory network 
downstream of mTOR complex 1. Mol Cell: 39(2):171-183.  
Eastman A.; (1999). The mechanism of action of cisplatin: from adducts to apoptosis. In Cisplatin: Chemistry 
and Biochemistry of a Leading Anticancer Drug. (Lippert, B., Ed.). Weinheim, Wiley-VCH, Zurich: 111–134.  
Elstrom R.L., Bauer D.E., Buzzai M., et al.; (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer 
Res: 64(11):3892 -3899. 
Espineda C.E., Chang J.H., Twiss J., Rajasekaran S.A., Rajasekaran A.K.; (2004). Repression of Na,KATPase 
beta1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell: 15:1364-73. 
Esteller M.; (2000). Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation 
of DNA repair genes. Eur J Cancer: 36: 2294-300. 
Feng Z., Levine A.J.; (2010). The regulation of energy metabolism and the IGF-1/-mTOR pathways by the 
p53 protein. Trends CellBiol. 20(7):427-434. 
Fernandez-Silva P., Enriquez J. A. and Montoya J.; (2003) Replication and transcription of mammalian 
mitochondrial DNA. Exp. Physiol. 88: 41–56.  
Ferry K.V., HamiltonT.C., Johnson S.W.; (2000). Increased nucleotide excision repair in cisplatin-resistant 
ovarian cancer cells: Role of ercc1-xpf. Biochem Pharmacol. 60:1305^13. 
Fishel R.; (2001). The Selection for Mismatch Repair Defects in Hereditary Hypothesis Nonpolyposis 
Colorectal Cancer : Revising the Mutator. Cancer Res. 61, 7369. 
Fraser M., Leung B.M., Yan X., Dan H.C., Cheng J.Q., Tsang B.K.; (2003). p53 is a determinant of X-linked 
inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer 
Research: 63(21):7081–7088. 
Frezza C. and Gottlieb E.; (2009). Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 
19:4–11. 
Fuertes M.A., Castilla J., Alonso C., Perez J.M.; (2003). Cisplatin biochemical mechanism of action: from 
cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. 
Curr Med Chem. 10:257–266. 
Fuertes M.A., Alonso C., Perez J.M.; (2003). Biochemical modulation of Cisplatin mechanisms of action: 
enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 103(3):645–62. 
80 
 
Fung-Kee M., Oliver T., Elit L., Oza A., Hirte H., Bryson P.; (2007). Optimal chemotherapy treatment for 
women with recurrent ovarian cancer. Current Oncology: 14(5):195.  
Galanski M.; (2006). Recent developments in the field of anticancer platinum complexes. Recent Pat 
Anticancer Drug Discov. 1:285–95. 
Garber K.; 2006. Energy deregulation: licensing tumor to grow. Science: 312, 1158-1159. 
Gately D. P. and Howell S. B.; (1993). Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. 
Cancer: 67:1171–1176. 
Gatenby R.A. and Gillies R.J.; (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 
4(11):891-9. Geisler J.P., Goodheart M.J., Sood A.K., Holmes R.J., Hatterman-Zogg M.A.,  
Godwin A.K., Meistert A., O’Dwyer P.J., Huangt C.S., Hamilton T.C., Anderson M.E.; (1992). High resistance 
to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. 
Proc Natl Acad Sci U S A: 89(7):3070–4.  
Goldring E.S., et al.; (1970). The petite mutation in yeast. Loss of mitochondrial deoxyribonucleic acid during 
induction of petites with ethidium bromide. J Mol Biol. 52(2):323-35. 
Gonzalez V.M., Fuertes M.A.,Alonso C., Perez J.M.; (2001). Is cisplatin induced cell-death always produced 
by apoptosis? Mol Pharmacol. 59:657–663 
Gottlieb E., Tomlinson I.P.; (2005). Mitochondrial tumour suppressors: a genetic and biochemical update. 
Nat Rev Cancer: 5 (11):857-866. 
Green A.S., Chapuis N., Lacombe C., et al.; (2011). LKB1/AMPK/m-TOR signaling pathway in hematological 
malignancies: from metabolism to cancer cell biology. Cell Cycle: 10(13).  
Green A. E. and Garcia A. A.; (2012). Ovarian Cancer. Medscape Reference. 
Guppy M., Greiner E., Brand K.; (1993). The role of the Crabtree effect and an endogenous fuel in the 
energy metabolism of resting and proliferating thymocytes. Eur J Biochem. 212(1): 95-99 
Harper. M. E., Antoniou A., Villalobos-Menuey E., Russo A., Trauger R., Vendemelio M., George A., 
Bartholomew R., Carlo D., Shaikh. et al.; (2002). Characterization of a novel metabolic strategy used by 
drug-resistant tumor cells. FASEB J. 16: 1550–1557. 
Hanahan D. and Weinberg R.A.; (2011). Hallmarks of Cancer: The Next Generation. Cell: 144: 646-674 
Hatzivassiliou G. et al.; (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell: 
8:311-321 
Hay N.; (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell: 8(3):179-183. 
Heintz A.P., Odicino F., Maisonneuve P., et al.; (2001). Carcinoma of the ovary. J Epidemiol Biostat: 6(1): 
107-38. 
Himeno S., Imura N.; (2000). HeLa cell transformants overproducing mouse metallothionein show in vivo 
resistant to cis-platinum in nude mice. Jpn J Cancer Res. 91:91–98.  
Hishikawa Y., Koji T., Dhar D.K., Kinugasa S., Yamaguchi M., Nagasue N.; (1999). Metallothionein 
expression correlates with metastatic and proliferativ epotential in squamous cell carcinoma of the 
esophagus. Br J Cancer: 81:712–720.  
Holzer A.K., Katano K., Klomp L.W., Howell S.B.; (2004). Cisplatin rapidly down-regulates its own influx 
transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res. 2004;10(19):6744–9. 
Hsu P.P. and Sabatini D.M.; (2008). Cancer Cell Metabolism: Warburg and Beyond. Cell: 134: 703-707. 
81 
 
Huncharek M., Kupelnick B.; (2001). Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis 
of 6,689 subjects from 8 observational studies. Nutr Cancer: 40: 87-91. 
Inoki K., Li Y., Zhu T., et al., (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses m-TOR 
signalling. Nat Cell Biol. 4(9):648-657. 
International Federation of Gynecology and Obstetrics (1989). Annual report on the results of treatment in 
gynecological cancer. Int J Gynecol Obstet. 28:189-190. 
Ishida S., Lee J, Thiele D.J. and Ira Herskowitz I.; (2002). Uptake of the anticancer drug cisplatin mediated 
by the copper transporter Ctr1 in yeast and mammals. PNAS: 99. 
Ishikawa T. and Ali-Osman F.; (1996). Coordinated induction of MRP/GS-X pump and gamma-
glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem. 271(25):14981–8. 
Isidoro A., Martinez M., Fernandez P.L., Ortega A.D., Santamaria G., Chamorro M., et al.; (2004). 
Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and 
oesophageal cancer. Biochem J. 378:17-20. 
Jascur T. and Boland C.R.; (2006). Structure and function of the components of the human DNA mismatch 
repair system. Int J Cancer: 119:2030-5.  
Jemal A., Siegel R., Ward E., Murray T., Xu J., et al.; (2007). Cancer statistics, 2007. CA Cancer J Clin: 57: 43–
66. 
Joerger M., Huitema A. et al.; (2007). Population pharmacokinetics and pharmacodynamics of paclitaxel 
and carboplatin in ovarian cancer patients: a study by the European organization for research and 
treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. 
Clinical Cancer Research: 13(21):6410.  
Jordan P. and Carmo-Fonseca M.; (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cell. 
Mol. Life Sci. 57, 1229 
Judson I. and Kelland L.R.; (2000). New Development and approaches in the platinum Arena. Drugs: 59:29-
36. 
Kartalou M. and Essigmann J. M.; (2001). Mechanisms of resistance to cisplatin. Mutation Res. 478: 23 – 
43. 
Kastenmüller G., Römisch-Margl W., Wägele B., Altmaier E., Suhre K.; (2011). metaP-Server: A Web-Based 
Metabolomics Data Analysis Tool. J Biomed Biotechnol. pii: 839862.  
Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., Kuo Y.M., Rochdi M. and Howell S.B.; 
(2002). Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of 
copper. Cancer Res. 62(22):6559–65.  
Kelland L.R.; (2000). Preclinical perspectives on platinum resistance.Drugs: 59, 1. 
Kennedy A.W., Biscotti C.V., Hart W.R., Webster K.D.; (1989). Ovarian clear cell adenocarcinoma. Gynecol 
Oncol. 32(3): 342-9. 
Kim D.H., Sarbassov D.D., Ali S.M., et al.; (2002). mTOR interacts with raptor to form a nutrient-sensitive 
complex that signals to the cell growth machinery. Cell: 110(2):163-175. 
King, M.P. and G. Attardi (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by 
complementation. Science 246(4929): p. 500-3. 
Kinlaw W.B., Quinn J.L., Wells W.A., Roser-Jones C., Moncur J.T.; (2006). Spot 14: a marker of aggressive 
breast cancer and a potential therapeutic target. Endocrinology: 147:4048–55. 
82 
 
Koberle B,MastersJRW, HartleyJA,Wood RD.; (1999). Defective repair of cisplatin-induced DNA damage 
caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 9:2738.  
Koberle B., Tomicic M.T., Usanova S., Kaina B.; (2010). Cisplatin resistance: preclinical findings and clinical 
implications. Biochim Biophys Acta. 1806:172–82. 
Komatsu M., Sumizawa T., Mutoh M., Chen Z.S., Terada K., Furukawa T., Yang X.L., Gao H., Konishi I., 
Kuroda H., Mandai M.; (1999). Review: gonadotropins and development of ovarian cancer. Oncology: 57 
Suppl 2: 45-8. 
Kolasa I.K., Rembiszewska A., Janiec-Jankowska A., Dansonka-Mieszkowska A., Lewandowska A.M., 
Konopka B. and Kupryjanczyk J.; (2006). PTEN mutation, expression and LOH at its locus in ovarian 
carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol. 103(2): 692–697. 
Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D. Ferreira G., Iyer N., LaRusch J., Pak B., 
Taghavi P., Semenza G.L.; (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor1. 
Cancer Res. 63:1138–1143.;  
Kroemer G. and Pouyssegur J.; (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 
13(6):472-82. 
Kuhajda F.P; (2000): Fatty acids synthase and human cancer: new perspective on its role in tumor biology. 
Nutrition: 16: 202-208.  
Kuhajda F.P; (2006). Fatty acids synthtase and human cancer: new application of an old pathway. Cancer 
Res. 66:5977-5980. 
Kulawiec M., Safina A., Desouki M.M., Still I., Matsui S.I., Bakin A. et al.; (2008). Tumorigenic 
transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol Ther. 
7:1732-43. 
Kunkel T.A. and Erie D.A.; (2005). DNA mismatch repair. Annu Rev Biochem. 74:681-710.; 
Kurman R.J., Shih I. M.; (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed 
unifying theory. Am J Surg Pathol. 34:433–443. 
Lautier D., Canitrot Y., Deeley R.G., Cole S.P.; (1996). Multidrug resistance mediated by the multidrug 
resistance protein (MRP) gene. Biochem Pharmacol. 52(7):967–77.  
Lee H.C., Yin P.H., Lin J.C., Wu C.C., Chen C.Y., Wu C.W., et al.; (2005). Mitochondrial genome instability 
and mtDNA depletion in human cancers. Ann N Y Acad Sci. 1042:109-22. 
Lehninger A.L., Nelson D.L., Cox M.M.; (1993). Principles of Biochemistry (II Edition). Worth; New York: 
1993 
Liedert B., Materna V., Schadendorf D., Thomale J., Lage H.; (2003). Overexpression of cMOAT 
(MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest 
in melanoma cells resistant to cisplatin. J Invest Dermatol. 121(1):172–6.  
Lim M.C., Lee D.O., Kang S. et al., (2009). Clinical manifestations in patients with ovarian clear cell 
carcinoma with or without co-existing endometriosis. Gynecol Endocrinol: 25:435-40.  
Lim M.C., Chun K.C., Shin S.J., et al.; (2010). Clinical presentation of endometrioid epithelial ovarian cancer 
with concurrent endometriosis: a multicenter retrospective study. Cancer Epidemiol Biomarkers Prev. 
19:398-404. 
Li X. M., Ganmaa D., Sato A.; (2003). The experience of Japan as a clue to the etiology of breast and ovarian 
cancers: relationship between death from both malignancies and dietary practices. Medical Hypotheses; 60 
(2): 268-275. 
83 
 
Luciani A. M., Grande S., Palma A., Rosi A., Giovannini C., Sapora O., Viti V., Guidoni L. ; (2009). 
Characterization of 
1
H NMR detectable mobile lipids in cells from human adenocarcinomas. FEBS J. 27, 333-
346. 
Lum J.J., Bui T., Gruber M., et al.; (2007). The transcription factor HIF-1alpha plays a critical role in the 
growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 21(9):1037-1049. 
Luo Z., Zang M., Guo W.; (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell 
growth. Future Oncol. 6(3):457-470. 
Macheda M.L, Rogers S., Best J.D.; (2005). Molecular and cellular regulation of glucose transporter (GLUT) 
proteins in cancer. J Cell Physiol. 202(3):654-662. 
Mambo E., Chatterjee A., Xing M., Tallini G., Haugen B.R., Yeung S.C., et al.; (2005). Tumor-specific 
changes in mtDNA content in human cancer. Int J Cancer: 116:920-4. 
Mansfield K.D., Guzy R.D., Pan Y., et al.; (2005). Mitochondrial dysfunction resulting from loss of 
cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 1(6):393-399. 
Matoba S., Kang J.G., Patino W.D., et al.; (2006). p53 regulates mitochondrial respiration. Science: 312 
(5780):1650-1653. 
Meijer C., TImmer A., DeVries E.G., Groten J.P, Knol A., Zwart N., Sleijefer D.T., Mulder N.H.; (2000). Role 
of metallothionein in cisplatin sensitivity of germ-cell tumors. Int J Cancer :85(6):777–781.  
Menendez J.M. and Lupu R.; (2007). Fatty acid synthase and the lipogenic phenotype in cancer 
pathogenesis. Nat Rev Cancer 7: 10. 763-777. 
Menedez J.M.; (2010). Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements 
of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochemica an Biophysica Acta: 
1801:381-391. 
Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., 
Guarente L., et al.; (2012). Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. 
Nature: 481: 380–384. 
Milgraum L.Z. et al.; (1997). Enzymes of the fatty acid synthase pathway are highly expressed in in situ 
breast carcinoma. Clin. Cancer Res. 3:2115-2120. 
Mitchell P.; (1961). Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type 
of mechanism. Nature: 191: 144-8.  
Miura N., Sugiyama T. and Akiyama S.I.; (2000). Copper-transporting P-type adenosine triphosphatase 
(ATP7B) is associated with cisplatin resistance. Cancer Res. 60(5):1312–6.  
Mizumachi T., Muskhelishvili L., Naito A., Furusawa J., Fan C.Y., Siegel E.R., et al.; (2008). Increased 
distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared 
with normal prostate cells. Prostate: 68:408-17. 
Moggs J.G., Szymkowski D.E., Yamada M., et al.; (1997) Differential human nucleotide excision repair of 
paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res. 25(3):480–91.  
Montopoli M., Bellanda M., Lonardoni F., Ragazzi E., Dorigo P., Froldi G., Mammi S., Caparrotta L.; (2009). 
"Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets: 
11(2):226-35.  
Morch L.S., Lokkegaard E., Andreasen A.H., Kruger-Kjaer S. and Lidegaard O.; (2009). Ormon Therapy and 
ovarian cancer. Jama: 302(3): 298-305. 
84 
 
Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel 
N.S., DeBerardinis R.J.; (2012). Reductive carboxylation supports growth in tumour cells with defective 
mitochondria. Nature: 481: 385–388 
Muramatsu Y., Yasegawa Y., Fukano H., Ogawa T., Namuba M., Mour S., Fujimoto Y., Matsuura H., Takai 
Y., Mori M.; (2000). Metallothionein immunoreactivitiy in head and neck carcinomas - special reference to 
clinical behaviors and chemotherapy responses. Anticancer Res. 20:257 
Murdoch W.J.; (2003). Metaplastic potential of p53 down-regulation in ovarian surface epithelial cells 
affected by ovulation. Cancer Lett. 191(1): 75-81. 
Musille P. M. and Kohn J. A.; (2013). Phospholipid – Driven gene regulation. FEBS Lett. 
Mussini C., Pinti M., Bugarini R., Borghi V., Nasi M., Nemes E., et al.; (2005). Effect of CD4-monitored 
treatment interruption on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS: 
19:1627–33. 
Mutlu G.M., Scott Budinger G.R., Chandel N.S.; (2010). Mitochondrial metabolism and ROS generation are 
essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107:8788–8793.  
Nagley P. and Linnane A.W.; (1970). Mitochondrial DNA deficient petite mutants of yeast. Biochem Biophys 
Res Commun. 39(5): p. 989-96. 
Nakayama K., Miyazaki K., Kanzaki A., Fukumoto M., Takebayashi Y.; (2001). Expression and cisplatin 
sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell 
lines. Oncol Rep. 8(6):1285–7.  
Nakayama K., Kanzaki A., Ogawa K., Miyazaki K., Neamati N., Takebayashi Y.; (2002). Copper-transporting 
P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian 
carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer: 
101(5):488–95.  
Neeraj L., Srinivasa R. P., Raghunandan V., Alampady K. S., Phyllis C. H., Najla F.; (2011) Histologic, 
Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment1. 
RadioGraphics: 31:625-646 
NelsonD.L and Cox M.M; (2002). I Principi di Biochimica di Lehninger, 3
a
 ed., Bologna, Zanichelli. 
Ookhtens M., Kannan R., Lyon I., Baker N.; (1984). Liver and adipose tissue contributions to newly formed 
fatty acids in an ascites tumor. Am J.Physiol. 247:146-153.;  
Ohta S.; (2006). Contribution of somatic mutations in the mitochondrial genome to the development of 
cancer and tolerance against anticancer drugs. Oncogene: 25:4768–4776 
Papandreou I., Cairns R.A., Fontana L., et al.; (2006). HIF-1 mediates adaptation to hypoxia by actively 
downregulating mitochondrial oxygen consumption. Cell Metab. 3(3):187-197. 
Pastorino J.G., Hoek J.B., Shulga N.; (2005). Activation of glycogen synthase kinase 3beta disrupts the 
binding of hexokinase II tomitochondria by phosphorylating voltage-dependent anion channel and 
potentiates chemotherapy-induced cytotoxicity. Cancer Res. 65(22):10545-10554. 
Park S.Y., Chang I., Kim J.Y., Kang S.W., Park S.H., Singh K. et al.; (2004). Resistance of mitochondrial DNA-
depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem. 279:7512–7520. 
Park M.S., De Leon M., Devarajan P.; (2002). Cisplatin induces apoptosis in LLC-PK1 cells via activation of 
mitochondrial pathways. J Am Soc Nephrol .13:858– 865;  
Pasetto L.M., D’Andrea M.R., Brandes A.A., Rossi E., Monfardini S.; (2006). The development of platinum 
compounds and their possible combination. Crit Rev Oncol Hematol: 60 :59–75. 
85 
 
Patiar S. and Harris L.; (2006). Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr 
Relat Cancer: 13 :61-75. 
Payet D.G., Sip F., Leng M.; (1993). Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-
2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA. Nucl. 
Acids Res. 21, 5846. 
Peleg-Shulman T. and Gibson D. J.; (2001). Cisplatin-protein adducts are efficiently removed by glutathione 
but not by 5′-guanosine monophosphate. Am.Chem. Soc. 123, 3171. 
Pettersen E.O., Schwarze P.E., Dornish J.M., Nesland J.M.; (1986). Antitumour effect of benzylidene-
glucose (BG) in rats with chemically induced hepatocellular carcinoma. Anticancer Res. 6(2):147–52. 
Peltomaki P.; (2003). Role of DNA mismatch repair defects in the pathogenesis of human cancer. 
JClinOncol. 21:1174-9. 
Peyrone M.; (1845). Ann. Chem. Pharm. 51, 1. 
Pitkänen S. and Robinson B.H.; (1996)Mitochondrial complex I deficiency leads to increased production of 
superoxide radicals and induction of superoxide dismutase. J Clin Invest. 98: 345–351,. 
Pizer E.S., Jackisch C., Wood F.D., Pasternack G.R., Davidson N.E., Kuhajda F.P.; (1996). Inhibition of fatty 
acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56:2745–7. 
Pouyssegur J., Dayan F., Mazure N.M.; (2006). Hypoxia signalling in cancer and approaches to enforce 
tumour regression. Nature: 441(7092):437-443. 
Preston TJ, Abadi A, Wilson L, Singh G.; (2001). Mitochondrial contribution to cancer cell physiology: 
potential for drug development. Adv Drug Deliv Rev. 49:45–61. 
Quirk J.T. and Natarajan N.; (2005). Ovarian cancer incidence in the United States, 1992-1999. Gynecol 
Oncol. 97(2): 519-23. 
Rabik. C. A. and Dolan M. E.; (2007). Molecular mechanisms of resistance and toxicity associated with 
platinating agents. Cancer Treatment Rev. 33: 9 – 23.  
Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternack G.R., Kuhajda F.P., Hamilton S.R.; 
(1997). Elevated expression of fatty acid synthase and fatty acid synthetic activity in colonrectal neoplasia. 
Am J.Physiol. 150:201-208 
Rebbeck T.R., Kauff N.D., Domchek S.M.; (2009). Meta-analysis of risk reduc tion estimates associated with 
risk-reducing salpingo-ophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst: 101(2): 80–7 
Reitzer L. J., Wice B. M., Scheffler I. C.; (1979).Evidence that glutamine, not sugar, is the major energy 
source for cultured HeLa cells. J. Biol. Chem. 254, 2669-2676. 
Rosenberg B., VanCamp L., Krigas T.; (1965). Nature: 205, 698. 
Rossing M.A, Tang M.T, Flagg E.W., Weiss L.K. and Wicklund K.G.; (2004). A case-control study of ovarian 
cancer in relation to infertility and the use of ovulation-inducing drugs. Am J. Epidemiol. 160(11): 1070-8.  
Rudin C.M., Yang Z., Schumaker L.M., VanderWeele D.J., Newkirk K., Egorin M.J., Zuhowski E.G., Cullen 
K.J.; (2003). Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 
63(2):312–8.  
Saiati L.M. and Amir-Ahmady B.; (2001). Dietary regulation of expression of glucose-6-phosphate 
dehydrogenase. Annu Rev Nutr. 21:121–40.  
86 
 
Salani R., Kurman R.J., Giuntoli R., Gardner G., Bristow R., Wang T.L. and Shih I.M.; (2008). Assessment of 
TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate 
than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer:18(3): 487–491. 
Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., Goodman M., Howell S.B.; (2004). 
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, 
and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 10(14):4661–9. 
Scholl C., Gilliland D.G., Frohling S.; (2008). Deregulation of signaling pathways in acute myeloid leukemia. 
Semin Oncol. 35 (4):336-345. 
Selvanayagam P. and Rajaraman S.; (1996). Detection of mitochondrial genome depletion by a novel cDNA 
in renal cell carcinoma. Lab Invest. 74:592-9. 
Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C.; (2003). Enhanced cisplatin cytotoxicity 
by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63:1311-6.  
Semenza G.L.; (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE, 2007: (407):cm8. 
Semenza G.L.; (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer: 3(10):721-732. 
Shackelford D.B. and Shaw R.J.; (2009). The LKB1-AMPK pathway: metabolism and growth control in 
tumour suppression. Nat Rev Cancer: 9(8):563-575. 
Shaul Y.; (2000). c-Abl: activation and nuclear targets. Cell Death and Differentiation: 7(1):10–16.  
Shaw R.J; (2006). Glucose metabolism and cancer. Curr Opin Cell Biol. 18(6):598-608; Bui T. and  
Schrenk D., Baus P.R., Ermel N., Klein C., Vorderstemann B., Kauffmann H.M.; (2001). Up-regulation of 
transporters of the MRP family by drugs and toxins. Toxicol Lett. 120(13):51–7.  
Siddik Z.H.; (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene: 
22(47):7265–79. 
Siegsmund M.J., Marx C, Seeman O, Schummer B, Steidler A, Toktomambetova L, Kohrmann K-U, 
Rassweiler J, Alken P.; (1999). Cisplatin-resistant bladder carcinoma cells: enhanced expression of 
metallotioneins. Urol Res. 27:157–163. [ 
Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J. and Shih I.; (2003). Mutations in BRAF 
and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 95(6): 
484–486. 
Soslow R.A.; (2008). Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 27(2):161-
74. 
Soti C., Racz A., Csermely P. J.; (2002). Heat shock proteins as emerging therapeutic targets. Biol.Chem. 
277, 7066. 
Speelmans G., Staffhorst R.W., Versluis K., Reedijk J., de Kruijff B.; (1997). Cisplatin complexes with 
phosphatidylserine in membranes. Biochemistry: 36, 10545. 
Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., 
Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., 
Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan 
A.M.; (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. 
Nature: 457(7231):910-4. 
Stojic L., Brun R., Jiricny J.; (2004). Mismatch repair and DNA damage signalling. DNA Repair (Amst): 
3(89):1091–101. 
87 
 
Suzuki H., Itoh F.,Toyota M., et al.; (1999). Distinctmethylation pattern andmicrosatellite instability in 
sporadic gastric cancer. Int J Cancer: 83:309-13.  
Swinnen J.V., Brusselmans K., Verhoeven G.; (2006). Increased lipogenesis in cancer cells. New players, 
novel targets. Curr. Opin. Clin.Nutr. Metab. Care: 9:358-365. 
Taanman J.W.; (1999). The mitochondrial genome: structure, transcription, translation and replication. 
Biochim Biophys Acta: 1410:103-23. 
Tacka K. A., Dabrowiak J. C., Goodisman J., Penefsky H. S. and Souid A. K.; (2004). Effects of cisplatin on 
mitochondrial function in Jurkat cells. Chem. Res. Toxicol. 17: 1102–1111.  
Thompson C.B.; (2006). Cancer’s sweeth tooth. Cancer Cells: 9:419-420.; Garber K.; (2006). Energy 
deregulation licensing tumors to grow. Science: 312:1158-1159. 
Tong L. (2005). Acetyl-Coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug 
discovery. Cell Mol. Life Sci. 62:1784-1803. 
Toyoda H., Mizushima T., Satoh T., Izuka N., Nomoto A., Chiba H., Mita M., Naganuma A., Siu L.L., 
Banerjee D., Khurana R.J., Pan X., Pflueger R., Tannock I.F.; (1998). The prognostic role of p53, 
metallothionein, P-glycoprotein, and MIB-1 in muslce-invasive urothelial transitional cell carcinoma. Clin 
Cancer Res. 4:559–564.  
Tseng L.M., Yin P.H., Chi C.W., Hsu C.Y., Wu C.W., Lee L.M., et al.; (2006). Mitochondrial DNA mutations 
and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer: 45:629-38. 
Vander Heiden M.G., Cantley L.C., Thompson C.B.; (2009). Understanding the Warburg Effect: The 
Metabolic Requirements of Cell Proliferation. Science: 324:1029-1033. 
Vella N., Aiello M. et al.; (2011). 'Genetic profiling'and ovarian cancer therapy (Review) Molecular medicine 
reports: 4:771–777. 
Viniegra J.G., Losa J.H., Sánchez-Arévalo V.J., et al.; (2002). Modulation of PI3K/Akt pathway by E1a 
mediates sensitivity to cisplatin. Oncogene: 21(46):7131–7136.  
Vincent T. DeVita SHSAR, (2001). Principles and Practice of Oncology Single Volume. Cancer. 
Wallace D.C.; (2011). Bioenergetic origins of complexity and disease. Cold Spring Harb Symp Quant 
Biol. 76:1-16. 
Wang D and Lippard S.; (2005). Cellular processing of platinum anticancer drugs. Nature Reviews Drug 
Discovery: 4(4):307–320.  
Warburg O., Wind F., Negelein E.; (1927). The metabolism of tumors in the body. J Gen Physiol. 8(6):519-
530 
Warburg O.; (1956). On the origin of cancer cells. Science: 123(3191):309-314.].  
Weber K., Ridderskamp D., Alfert M., Hoyer S., Wiesner R.J.; (2002). Cultivation in glucosedeprived 
medium stimulates mitochondrial biogenesis and oxidative metabolism in HepG2 hepatoma cells. Biol 
Chem. 383:283-90. 
Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., 
Weinhouse S.; (1976). The Warburg hypothesis fifty years later. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. 
Oncol. 87:115–126. 
Welsh C., Day R., McGurk C., Masters J.R.,Wood R.D., Koberle B.; (2004). Reduced levels of XPA, ERCC1 
and XPF DNA repair proteins in testis tumor cell lines. IntJ Cancer: 110:352-61. 
88 
 
Whittemore A.S, Harris R., Itnyre J.; (1992). Characteristics relating to ovarian cancer risk: collaborative 
analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative 
Ovarian Cancer Group. Am J Epidemiol. 136(10): 1184-203. 
Wise D.R., Ward P.S., Shay J.E., Cross J.R., Gruber J.J., Sachdeva U.M., Platt J.M., Dematteo R.G., Simon 
M.C., Thompson C.B.; (2011). Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-
ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci. 108: 19611–19616.  
Witte A.B., (2005). Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes 
of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39(5):696–703.  
Wokolorczyk D., Gliniewicz B., Sikorski A., et al.; (2008). A range of cancers is associated with the Testa J.R. 
and Tsichlis P.N.; (2005). AKT signaling in normal and malignant cells. Oncogene: 24(50):7391-
7393.rs6983267 marker on chromosome 8. Cancer Res. 68(23):9982-9986. 
Wu C.W., Yin P.H., Hung W.Y., Li A.F., Li S.H., Chi C.W., et al.; (2005). Mitochondrial DNA mutations and 
mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer: 44:19-28. 
Xia J., Psychogios N., Young N., Wishart D.S.; (2009). MetaboAnalyst: a web server for metabolomic data 
analysis and interpretation. Nucl. Acids Res. 37: W652-660. 
Xia J. and Wishart D.S.; (2011). Web-based inference of biological patterns, functions and pathways from 
metabolomic data using MetaboAnalyst. Nat Protoc. 6(6):743-760.  
Xiao H., Verdier-Pinard P. et al.; (2006). Insights into the mechanism of microtubule stabilization by Taxol. 
Proc Natl Acad Sci U S A: 103(27):10166–10173. 
Yang D. Wang M.T., Tang Y., et al.; (2010). Impairment of mitochondrial respiration in mouse fibroblasts by 
oncogenic H-R AS (Q61L). Cancer Biol Ther. 9(2):122-133. 
Yin P.H., Lee H.C., Chau G.Y., Wu Y.T., Li S.H., Lui W.Y., et al.; (2004). Alteration of the copy number and 
deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer: 90:2390-6. 
Yu M., Zhou Y., Shi Y., Ning L., Yang Y., Wei X., et al.; (2007). Reduced mitochondrial DNA copy number is 
correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life 59:450-7. 
Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J.; (1996). Repair of cisplatin--DNA adducts by the 
mammalian excision nuclease. Biochemistry: 35(31):10004–13.  
Zorbas H. and Keppler B.K.; (2005). Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? 
Chembiochem. 6(7):1157–66. 
